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ABSTRACT 
As electronic cigarettes become more prevalent in society, their use as a delivery 
mechanism for drugs of abuse has increased. Electronic cigarette liquids present a complex 
matrix due to the lack of regulation, and therefore standardization, in their manufacturing. 
Due to the lack of published data, development of new analytical methods to accommodate 
this complexity was deemed necessary.  
Gas chromatography-mass spectrometry (GC/MS) and liquid chromatography-
tandem mass spectrometry (LC/MS/MS) methods were developed to identify the flavorants 
of the electronic cigarette liquids as well as identify and quantify nicotine and common 
drugs of abuse used with these devices. 
Seven drugs of abuse were investigated: methamphetamine, heroin, cocaine, 
fentanyl, JWH-081, JWH-018, and AM-2201. Electronic cigarette liquids from five 
manufacturers were sampled. From each manufacturer five “flavors” of liquids were 
chosen.  Each liquid “flavor” was tested at the manufactures reported nicotine 
concentrations of 0 mg/mL, 12 mg/mL, and 24 mg/mL to give a total of 75 electronic 
cigarette liquid samples.  
vi 
Liquid-liquid extraction was performed on all samples prior to analysis by GC/MS 
and LC/MS/MS. Analysis was performed in replicates of five to identify the electronic 
cigarette liquid components as well as quantify nicotine and the four analytes of interest. 
For any electronic cigarette liquid labeled as containing 0 mg/mL of nicotine in which 
nicotine was identified, the sample was analyzed by GC/MS to quantify the nicotine level. 
These concentrations were compared to the naturally occurring levels of nicotine found in 
certain food products. 
Identification of the flavorants of the electronic cigarette liquids as well as the 
quantitation of nicotine and the four commonly abused drugs was accomplished using 
GC/MS and LC/MS/MS.  Samples of e-liquids labeled by the manufacturer as containing 
0 mg/mL of nicotine may contain detectable and quantifiable levels of nicotine.  
Quantitation of drugs of abuse may be affected by matrix components and was found to be 
dependent on both the specific e-liquid being used with the electronic cigarette as well as 
the analyte being investigated. 
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1. INTRODUCTION 
1.1 Electronic Cigarettes 
 Electronic cigarettes, also known as electronic nicotine delivery systems (ENDS) 
or simply e-cigarettes, are battery-operated inhalers that deliver nicotine to the user without 
the harmful combustion reactions of traditional tobacco cigarettes. There is no standard 
construction of e-cigarettes which allows different manufacturers to use different designs 
and components for their particular products.1  
 
1.1.1 Components 
While the construction of e-cigarettes is not standardized nor fully regulated, 
several components are common to many different manufacturers’ specific devices.1 The 
first component that is common across devices is the cartridge.  The cartridge contains the 
electronic cigarette liquid (also known as “e-liquid”). In most of the early-manufactured e-
cigarettes the cartridges were pre-filled before the device was sold. However, in newer e-
cigarettes the cartridges are refillable allowing the user to customize the e-liquid to their 
own particular liking. The e-liquids contain propylene glycol, vegetable glycerin, nicotine, 
and flavorant; however, the exact chemical make-up varies widely based on the 
manufacturer. The second component that is common across devices is the tube, also called 
the atomizer, which contains the heating element and through which the user inhales the e-
liquid vapor. The heating element vaporizes the e-liquid to form a mist that the user inhales. 
The user can generate this mist by either attaching a cartridge that is filled with e-liquid to 
the e-cigarette or by dripping e-liquid directly onto the atomizer. The last component which 
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is found in almost all devices is the battery, which can be disposable or rechargeable.1 
Figure 1 shows the components of an e-cigarette, which are common across different 
manufacturer’s devices. 
 
 
 
 
 
 
 
Figure 1. Common components of an e-cigarette
2
 
 
 
In addition to the variations in e-cigarette devices across manufacturers, these 
devices have also changed since they were invented in 2003.2 The early e-cigarettes, or 
first-generation devices, are designed to resemble traditional tobacco cigarettes containing 
pre-filled cartridges of e-liquid, an LED light that glowed when the user inhaled, and 
disposable lithium batteries. These first-generation devices were most commonly used by 
people who were attempting to quit smoking due to their similarity to traditional tobacco 
cigarettes.  
The second-generation devices that followed had greater ability to modify the 
device based on personal tastes. Second-generation devices are equipped with rechargeable 
batteries and cartridges that can be refilled with an e-liquid of the user’s choice. These 
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devices no longer resembled traditional tobacco cigarettes. In second-generation devices, 
users push a button to activate the atomizer which heats the e-liquid that can then be 
inhaled. This allowed users the ability to stop using the product at any point without fear 
that the battery would run out in between uses. The third-generation devices are designed 
to allow for the greatest customization based on user preferences. They consist of a large 
capacity battery and can be combined with atomizers and cartridges from second-
generation devices.2 The second and third-generation devices are found to be more 
commonly used by people whom exclusively vape, use e-cigarettes or similar products, 
while the first-generation products are found to be more commonly used by current or 
former smokers. Figure 2 shows the different generation devices that are currently available 
on the market. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Different generation e-cigarette devices available2 
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1.1.2 Public Health Perspective 
 The novel construction of current e-cigarettes, as well as the lack of regulation 
surrounding e-liquids, has prompted debate on e-cigarette use and effectiveness within the 
public health community.1,3-5 
 
1.1.2.1 Regulation 
 Currently e-cigarettes are not regulated by the Food and Drug Administration 
(FDA), unless they are marketed as being for therapeutic use.6 Tobacco products currently 
regulated by the FDA include cigarettes, cigarette tobacco, roll-your-own tobacco, and 
smokeless tobacco, however, the FDA has proposed a new rule that would require e-
cigarettes to fall under this regulation as well.6 If the proposed rule were to become law, 
manufacturers of e-cigarettes would be subject to the same regulations as makers of 
traditional tobacco products, including registering with the FDA, reporting ingredient 
listings, marketing products only after FDA review, and not distributing free samples.7 
 However, in addition to the regulations already in place, e-cigarettes would be 
subject to more regulations including minimum age limits, inclusion of health warnings, 
and prohibition of vending machine sales.7 Final action on this proposed rule is currently 
pending, after a ruling is made, makers of e-cigarettes would have two years after the final 
rule appears on the Federal Register to comply with the new regulations.7 
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1.1.2.2 Health Concerns 
Several concerns of the public health community surround the e-liquids being used 
with e-cigarettes.1,2,8 Lack of regulation of e-liquids allows manufacturers to sell these 
mixtures with large concentrations of nicotine, in some cases with concentrations 
exceeding 24 mg/mL of nicotine.1,9 A single traditional tobacco cigarette typically contains 
between 6-17 mg of nicotine, with a user only inhaling 1-2 mg of nicotine for each cigarette 
smoked.10 This high concentration of nicotine in e-liquids presents the possibility of 
nicotine poisoning if the e-liquids are accidentally ingested or spilled on the skin while 
attempting to refill a cartridge.1 Young children may accidently ingest e-liquids if they 
mistake them for candy due to their colors and appealing flavors such as blueberry and 
chocolate.1,8 While serious nicotine poisoning is rare when using traditional cigarettes, 
concentrated e-liquids may cause nicotine poisoning to become more commonplace, 
especially among children due to the lack of child resistant containers.1  
There is also concern surrounding the chemicals that are being used to produce 
different flavors of the e-liquid.2 Manufacturers use different chemical combinations to 
produce specific flavors and the user may not know what they are inhaling. While several 
of the chemicals that are used in the e-liquid flavorings have been approved for use in the 
food industry, the effects of using these chemicals by heating and inhalation have not been 
studied at length.2 The use of propylene glycol in e-liquids also raises some concerns 
among researchers.  Propylene glycol is used in some oral products but has not been studied 
for the effects produced with long term exposure to heating and inhalation.1 
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The public health community has concerns not just with the e-liquids, but with the 
use of the e-cigarettes as a whole.8,11–13 One concern stemming from the use of e-cigarettes 
is regarding secondhand exposure to the vapors that they produce.12 While e-cigarettes are 
designed to administer nicotine to the user without the harmful combustion products of 
traditional cigarettes, vapor is still exhaled by the user. Studies have shown that exhaled 
vapor contains significant levels of nicotine, propylene glycol and vegetable glycerin.12,14 
While these levels were found to be much lower when compared to traditional cigarettes, 
bystanders may still be involuntarily exposed to these chemicals as the use of e-cigarettes 
is currently allowed in locations where traditional cigarettes have been banned.12 
Another concern of the public health community is that the use of e-cigarettes may 
dissuade smokers from quitting their use of nicotine products completely.11 It is possible 
that some smokers who would have had the motivation to quit smoking will experience a 
decrease in motivation with the ability to use e-cigarettes in places where they cannot 
smoke traditional tobacco products.11 There is also the possibility that e-cigarettes could 
lead to an increase in nicotine addiction because smokers perceive them as a safer 
alternative to traditional cigarettes.8,13 Adolescents may use e-cigarettes more frequently 
when compared to traditional tobacco cigarettes because they find them more appealing 
and less likely to cause serious long term health problems.15 
 
1.1.2.3 Potential Health Benefits 
 While the public health community has many concerns surrounding the use of e-
cigarettes and the e-liquids used with them, they do acknowledge that there may be some 
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potential health benefits with the use of these products. One of the most common claims 
that is recognized by public health professionals is the potential for e-cigarettes to aid in 
smoking cessation.8,11,16–18  
 According to a survey by Dockrell et al. on smoking habits, just over half of 
smokers believe that the use of e-cigarettes would aid them in quitting smoking entirely.8 
The e-liquids used with e-cigarettes are available in a variety of nicotine concentrations, as 
well as nicotine free.  This allows e-cigarette users to slowly break their nicotine addiction 
while still going through the physical actions that they have associated with smoking which 
may prove to be a more difficult habit to break.19 Bullen et al. found that even when using 
an e-cigarette with an e-liquid that contained no nicotine the user’s desire to smoke was 
relived within ten minutes of use. The authors also found that e-cigarette use can aid in 
reducing cravings and withdrawal symptoms for users who are attempting to quit 
smoking.19 
 Wagener et al. conducted a study on the attitudes of smokers and their readiness to 
quit after one week of e-cigarette use.11 The participants of this study were current smokers 
who had no intent of quitting smoking within the next 30 days. In the experimentation 
phase of the study, the participants were given three popular brands of e-cigarettes and 
allowed to experiment with each one. At the end of the experimentation phase, the 
participants chose one of the e-cigarette brands they had tried to take home and use for one 
week. After the one-week trial period the participants were surveyed about their opinions 
of the products. The authors found that after one week of e-cigarette use the participants 
showed a significant increase in their confidence and readiness to quit smoking. They also 
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found that use of e-cigarettes does not appear to decrease smoker’s motivation to quit after 
one week of use.11 
 
1.1.3 Cultural Impact 
 As e-cigarettes become more prevalent in society they are beginning to have several 
cultural implications.  Awareness of e-cigarettes is growing among non-users, including 
adolescents, e-cigarettes are able to circumvent existing smoke-free laws due to the lack of 
regulation, and dedicated users have begun to form a “vaping” culture complete with its 
own technical language.  
 
1.1.3.1 Awareness of Electronic Cigarettes 
 In 2010 and 2011, web-based surveys were conducted to identify the increase of 
awareness of e-cigarettes within the population.13 In 2010, 40.9% of the population had 
heard of e-cigarettes.  This number jumped to 57.9% just one year later in 2011. While 
participants who identified as current smokers were more likely to have heard of e-
cigarettes (76.9%), half of the participants who identified as never smokers (50.1%) had 
heard of e-cigarettes by 2011.13 By 2013 86% of US adults had heard of e-cigarettes and 
this trend is expected to continue.20 
 Part of the reason for this trend may be based on how e-cigarettes are advertised.20 
Traditional cigarettes are strictly regulated in how they are advertised. However, these 
same regulations do not apply to e-cigarettes. Advertisements for e-cigarettes can appear 
on national television, in newspapers and magazines, and online.21 Pepper et al. found that 
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the top three ways that US adults first heard about e-cigarettes were from another person, 
for sale in a store, and from a television advertisement.20 
 Awareness in increasing not only among adults but among adolescents as well.15,22 
In a study conducted by Krishnan-Sarin et al., middle and high school students in 
Connecticut were surveyed about their knowledge of e-cigarettes.  They found that 84.3% 
of middle school students and 92% of high school students had heard of e-cigarettes. The 
percentage of high school students who had heard of e-cigarettes (92%) was found to be 
slightly higher than the overall percentage of US adults who had heard of e-cigarettes 
(86%). This may be due to the fact that adolescents spend more time using the Internet 
when compared with adults and e-cigarettes have a strong and growing Internet presence.15 
 
1.1.3.2 Initiation and Normalization of Smoking 
 Some in the public health community are concerned that the popularity and 
availability of e-cigarettes may cause an increase in initiation of use of nicotine containing 
products. They are also concerned that e-cigarettes may cause a normalization of smoking 
behavior. This concern stems from the fact that e-cigarettes are able to be used in places 
where traditional cigarettes are not, such as airports and restaurants.12,15 Krishnan-Sarin et 
al. also found that 3.5% of middle school students reported that they had tried an e-
cigarette, with an average age of initiation of 12.24 years.  Further 25.5% of middle school 
students surveyed, who identified as never-smokers, reported that they would be 
susceptible to e-cigarette use in the future.15 
10 
 These numbers were compared to those of high school students out of whom 25.5% 
reported that they had tried an e-cigarette, with an average age of initiation of 15.18 years. 
Out of the high school students surveyed who identified as never-smokers, 29.6% reported 
that they would be susceptible to e-cigarette use in the future.15 
 Krishnan-Sarin et al. also surveyed students to discern the type of e-liquid typically 
used.15 The most popular flavors used were sweet flavors (70.7%) and an e-liquid that 
contained no nicotine (40.6%). However, what is most concerning to public health 
professionals is that many of the adolescents who had first used e-cigarettes with an e-
liquid containing no nicotine were now using e-liquids that do contain nicotine. This 
suggests that while adolescents may be initiating e-cigarette use without nicotine, they may 
eventually become nicotine dependent. Another concerning fact for public health 
professionals is that 20.4% of middle and high school students who had used an e-cigarette 
did not know if the e-liquid they had used did in fact contain nicotine or not.15 
 
1.1.3.3 “Vaping” Culture 
 As e-cigarettes grow in popularity, dedicated users have begun to form a distinct 
culture.8,23,24 One theme that is common among e-cigarette users is that there is a learning 
curve that comes with using these devices.23 E-cigarettes have a few durable parts, and 
many different replacement parts. Dedicated users have found manufacturer starter kits, 
which come with all necessary components, to be unsatisfactory. These users instead create 
their own modified, custom devices by combining different batteries, atomizers, and e-
liquids. Users have also found that there is a trial and error process to selecting the best e-
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liquid for them. E-liquids are available in a wide variety of flavors and nicotine 
concentrations, allowing users to customize their experience. The last issue novice users 
encounter is how to operate the e-cigarette. Users have to activate the atomizer to heat the 
e-liquid by activating a switch and taking “priming puffs”, breathing in through the device 
without inhaling e-liquid, before actually inhaling the e-liquid vapor, which new users may 
have difficulty with.23 
 Another part of the distinct e-cigarette culture involves the language they use.23 
Some of the terminology used by e-cigarette users includes “vaping”, “attys”, “carts”, 
“blanks”, and “mods”. Vaping is a term used to describe the behavior of inhaling vaporized 
e-liquid through an e-cigarette. Attys is a term that is used to describe the atomizer, or 
heating element, of the e-cigarette. Carts is a term used to describe a cartomizer, which is 
a combined atomizer and cartridge and is available on some brands of e-cigarettes. Blanks 
is a term used to describe refillable e-liquid cartridges. Mods is a term used to describe 
modified e-cigarettes that no longer resemble traditional tobacco cigarettes but rather large 
cylinders. These are all terms that new users will have to learn to truly understand the 
vaping culture that surrounds e-cigarette use.23 
 Another prominent part of vaping culture is the fact that users tend to think that e-
cigarettes will help them quit smoking, or pose a smaller health risk when compared to 
traditional cigarettes.8,23 Many users, who were smokers of traditional cigarettes, reported 
beginning e-cigarette use with high concentrations of nicotine in e-liquid and then slowly 
progressing to lower concentrations of nicotine. Many users have also reported that their 
quality of life improved when switching from traditional cigarettes to e-cigarettes. Such 
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improvements in quality of life include no longer waking up coughing, improved senses of 
taste and smell, and the ability to breathe better during physical exertion such as walking. 
One user felt that the immediate benefits of e-cigarettes outweighed any long-term health 
risks, and several other users felt that the long-term health effects of e-cigarettes were not 
as detrimental as those of traditional cigarettes, even with a lack of published data to 
support these ideas.23 
 
1.2 Drugs of Abuse and Electronic Cigarettes 
 As electronic cigarettes grow in popularity they are increasingly being used as drug 
delivery mechanisms by users and discussed on internet forum pages, such as Drugs-
Forum, Bluelight, and Reddit.25–31 Many users have stated that they use e-cigarettes to 
abuse various drugs because they are able to use these devices in public places without 
suspicion.25,29,30 Users have also stated that they favor using e-cigarettes as a drug delivery 
mechanism because it provides them with a desirable high without the need to inject the 
drug they are abusing.28,29 Some of the drugs that users have stated success in abusing by 
e-cigarette include methamphetamine, cocaine, fentanyl, heroin, and various synthetic 
cannabinoids including AM-2201, JWH-081, and JWH-018.16-21  
 
1.2.1 Methamphetamine 
 Methamphetamine is an amphetamine derivative and is a central nervous system 
stimulant that was first prepared in 1919.32–34 It is classified as a Schedule II drug by the 
Drug Enforcement Administration (DEA), meaning it has a high potential for abuse and 
13 
limited medical uses. Methamphetamine is able to suppress feelings of fatigue while 
increasing mental alertness which has allowed it to be used as a treatment for attention 
deficit hyperactivity disorder (ADHD).33,34 It is also used illicitly by truckers and students 
who need to stay awake for long periods of time.35 As users begin to come down from the 
methamphetamine high, they may begin to feel irritable, restless, anxious, or depressed.35 
Methamphetamine is easily synthesized in a clandestine lab which makes it 
relatively easy to obtain for illicit use.33 Methamphetamine can be abused orally, 
intravenously, intranasally, or by smoking.32,33 When methamphetamine is in its crystalline 
form it can be vaporized effectively and absorbed very rapidly through the lungs making it 
ideal for use with an e-cigarette.33 Internet forum posts by users who have tried adding 
methamphetamine to e-liquids for use in an e-cigarette indicate that it is possible and not 
overly complicated. One user reported that she draws up a methamphetamine solution into 
a syringe as if she were going to inject it and then adds it to a cartridge that is half full of 
e-liquid.26 
Methamphetamine can be analyzed by a variety of analytical techniques. Some of 
these techniques include immunoassays, thin layer chromatography (TLC), gas 
chromatography (GC), liquid chromatography (LC), mass spectrometry (MS), Raman 
spectroscopy, ion mobility spectrometry, FTIR and with a nitrogen phosphorus 
detector.32,34,36 
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1.2.2 Cocaine 
 Cocaine is a central nervous system stimulant which is found in the leaves of the 
Erythroxylon coca plant and has been used since ancient times for religious, social, and 
medicinal purposes.32,33 It is classified as a Schedule II drug by the DEA. Cocaine is 
currently used medicinally as a topical anesthetic in ophthalmological procedures.32 
Cocaine is abused for its stimulant-like effects such as increased endurance, reduced 
fatigue, and euphoria.33,37 It has a strong reinforcing action, meaning that use of cocaine 
causes rapid psychological dependence to the drug.33 
Cocaine can be abused as either the hydrochloride salt form of the drug or as the 
free base form of the drug, which is known as crack. Cocaine can be abused orally, 
intravenously, intranasally, or by smoking.33,37 When cocaine is in the freebase form it can 
be readily vaporized and inhaled which leads to rapid absorption and an onset of effects 
within seconds.33 It is for this reason that users recommend using cocaine freebase when 
using an e-cigarette as a delivery mechanism.29  
Cocaine may be analyzed by a variety of analytical techniques. Some of these 
techniques include immunoassays, GC, LC, MS, flame ionization detection (FID), Fourier 
transform infrared spectroscopy (FTIR), Raman spectroscopy, and differential mobility 
spectrometry (DMS).32,38–40 
 
1.2.3 Heroin 
 Heroin is an analgesic drug which was first synthesized from morphine in 1874 and 
is three times as potent as morphine.32,33 It is classified as a Schedule I drug by the DEA, 
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meaning that it has a high potential for abuse and no accepted medical use. Heroin has 
increased lipid solubility compared to morphine which causes it to cross the blood-brain 
barrier faster causing an intense rush of euphoria that users crave.33 In addition to euphoria, 
heroin also produces effects such as analgesia, drowsiness, and a sense of detachment.  
Heroin can be abused intranasally, intravenously, and by smoking.32,33 Users have 
reported that vaporizing heroin using an e-cigarette gives them the strong initial rush of 
euphoria that they are looking to get from the drug.28 Users have also reported that they 
had the most success in abusing heroin via e-cigarette when the free base form of the drug 
was used.28 
Heroin can be analyzed by a variety of analytical techniques. Some of these 
techniques include immunoassay, GC, LC, FID, capillary electrophoresis (CE), MS, 
ultraviolet detection (UV), and electron capture detection.32,41 
 
1.2.4 Fentanyl 
 Fentanyl is a short acting, synthetic opioid analgesic that has a higher potency than 
either morphine or heroin.32,33 Fentanyl is classified by the DEA as a Schedule II 
compound. Fentanyl is currently used in combination with surgical anesthesia and is used 
to treat chronic and breakthrough pain in patients.32,42 Fentanyl is abused for its feelings of 
euphoria but also for its sedative effects.33  
Fentanyl can be abused orally, intranasally, intravenously, and by smoking.32,33 In 
Internet forums, users report using fentanyl gel patches in e-cigarettes. They allow the gel 
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from the fentanyl patch to dry down before mixing the crystals with the e-liquid of their 
choice.27  
Fentanyl is able to be analyzed by a number of analytical techniques, including 
immunoassay, GC, LC, MS, nitrogen phosphorus detection, electron capture, and UV 
detection.32 
 
1.2.5 Synthetic Cannabinoids  
 Synthetic cannabinoids are a class of psychoactive substances that exhibit similar 
effects compared to Δ9-tetrahydrocannabinol (THC) and bind to the cannabinoid receptors 
in the brain.43–45 Synthetic cannabinoids are relatively new to the illicit drug market, first 
making a significant appearance in late 2008. These products are frequently sold over the 
Internet and a marketed as “legal highs” due to the gray area surrounding their legality.46  
The DEA has controlled some of these compounds, however whenever one 
compound becomes scheduled new ones appear on the market leading to the emergency 
scheduling of compounds as they are identified.46 These compounds are typically abused 
by smoking. However, little is known about their toxicity due to a lack of published data 
and analytical information due to limited reference standards.43–45  
Synthetic cannabinoids are popular topics among internet drug forum posts, and the 
number of posts describing using synthetic cannabinoids in e-cigarettes is growing. The 
synthetic cannabinoid distributor K2TM Incense has begun selling an e-liquid spiked with 
synthetic cannabinoids, which is referred to as K2TM e-liquid, on their website. Products 
such as the K2TM e-liquid may end up creating a greater problem, and lead to more difficult 
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analysis of e-liquids suspected to contain drugs of abuse, due to the lack of reference 
standards for the newer synthetic cannabinoid compounds. 47 
 
1.3 Research Objective 
 The objective of this research was to determine if drugs of abuse that have been 
added to e-liquids could be detected using gas chromatography-mass spectrometry 
(GC/MS) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). We have 
determined what qualitative and quantitative methods are feasible for the analysis of these 
samples. The effect(s) that various e-liquid matrices had on detection and quantitation was 
also evaluated as part of method development and validation. 
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2. MATERIALS AND METHODS 
2.1 Instrument Theory 
2.1.1 Gas Chromatography-Mass Spectrometry 
 Gas chromatography (GC) is a mixture separation technique utilizing a gaseous 
mobile phase and a solid stationary phase.48 Target analytes are separated and resolved 
from one another based on their interactions with both the mobile and stationary phases. A 
GC instrument contains an injection port, capillary column, oven, and a detector. A sample 
enters the injection port, is vaporized, pushed onto the column where it interacts with the 
stationary phase, and then is sent to the detector. Separation and resolution of analytes is 
optimized by varying the GC components.48 
 The injection port is designed to aid in the minimization of band broadening. The 
two most common types of injection are split and splitless.48 In a split injection, the sample 
is introduced into the hot injection port, vaporized, and then a portion of the sample is 
mixed with carrier gas which is allowed to vent and the remaining portion of the samples 
are passed onto the column. In a splitless injection, the sample is introduced into the hot 
injection port, vaporized, and then the entire sample, mixed with carrier gas, is passed onto 
the column. Use of a splitless injection is beneficial for detecting trace components of a 
sample due to the fact that 80-95% of the sample will be transferred to the capillary 
column.48 
 Capillary GC columns are typically made of fused silica with a polyimide outer 
coating to protect the column.48 The inside diameter, stationary-phase film thickness, and 
column length vary based on the specific application(s). The capillary column is held 
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within the oven where it can be uniformly heated. Due to the thin cross-section of the 
column, it is extremely responsive to changes in temperature. This allows a gradient 
temperature program to be used. A gradient temperature program is when the temperature 
of the GC oven is able to be increased, decreased, or held constant throughout the run time 
to force analytes of interest off of the column and into the detector. There are many 
detectors capable of being interfaced to GC, one common detector is the mass spectrometer 
(MS).48 
 The MS separates and detects ions based on their mass to charge ratio (m/z).49 
Before the ions can be detected, they need to be generated from the sample as it exits the 
GC column. One way that these ions can be generated is by electron ionization (EI). This 
is done by exposing the sample to a stream of electrons, which have a greater amount of 
energy than the energy contained in the sample bonds, causing ionization to occur. 
Chemical bonds can be broken in a characteristic manner using EI to produce predictable 
and identifiable fragments, allowing fragmentation libraries to be created.49 
 Once the fragment ions are generated they enter the mass analyzer of the MS.49 The 
mass analyzer is how the instrument separates ions so that they may be recorded. One type 
of mass analyzer that is used in gas chromatography-mass spectrometry (GC/MS) is the 
quadrupole. A quadrupole consists of four parallel rods that have changing direct current 
(DC) and radio frequency (RF) fields applied to them. The DC and RF fields induce motion 
of the ions in such a way that the ions are sorted by m/z.  These fields are able to be changed 
to allow ions with a different m/z to reach the detector and can continue changing until all 
m/z values of interest have been allowed to reach the detector. Once all of the ions have 
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reached the detector, they are plotted as a function of time to produce a total ion 
chromatogram (TIC). The TIC can then be compared to a fragmentation library to 
determine the identity of the analyte.49 
 
2.1.2 Liquid Chromatography Tandem Mass Spectrometry 
 Liquid chromatography (LC) is a separation technique that utilizes a liquid mobile 
phase and a solid stationary phase.50 Target analytes are able to be separated and resolved 
from one another based on their interactions with both the mobile and stationary phases. A 
LC instrument contains a mobile phase reservoir, pump, valves, sample introduction 
component such as an auto sampler, and column. Once the sample has exited the column 
it can then enter a separate detector. Separation and resolution of analytes is optimized by 
varying the LC instrument components and mobile phases.50  
 The reservoir is made of an inert material, such as glass, to contain the mobile phase 
used for separation.50 The mobile phase reservoir must be designed in a way to ensure that 
no dissolved gases are present in the mobile phase prior to use. If only one mobile phase is 
used, the analyst is limited to an isocratic elution, however, if more than one mobile phase 
is used a gradient elution can be utilized. The composition of the mobile phase is chosen 
based on the types of analytes that are being separated.50 
 The stationary phase in an LC system consists of a packed column.50 The LC 
column is typically a stainless steel tube that is packed with a solid material that acts as the 
stationary phase for the analytes to interact with. The column packing material, length, and 
diameter selected is based on the target analytes for optimal separation. Due to the nature 
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of the stationary phase, the LC pump must push the mobile phase through the column at 
high, constant pressures. The pump delivers the mobile phase at the required pressure by 
utilizing a single or double reciprocating piston system. 50 
 Once the sample exits the analytical column it enters the detector.49 One type of 
detector that is used with LC is a tandem mass spectrometer (MS/MS). Before the sample 
can be introduced to the mass analyzer of the MS/MS, ionization must occur.  One such 
technique is electrospray ionization (ESI), which is an atmospheric ionization method 
where ions are produced at atmospheric pressure as opposed to in a vacuum. The sample, 
in liquid form, is pumped through a capillary and is aerosolized as it exits the capillary. 
The droplets are desolvated, generating the production of ions, which then flow into the 
MS.49 
 The mass analyzer in MS/MS can be set up in a triple quadrupole configuration.49 
This means that three quadruple filters are set up in a linear fashion with the first 
quadrupole (Q1) and the third quadrupole (Q3) being used as mass filters with the second 
quadrupole (Q2) being used as a collision cell. In MS/MS it is possible to run a multiple 
reaction monitoring (MRM) experiment.  In MRM, Q1 is set to select the precursor ion and 
accelerate it towards Q2 where fragmentation takes place as the ions collide with a neutral 
gas. The ions are then accelerated into Q3 which selects for the product ions and sorts the 
ions before sending them into the detector. The ions are then plotted on a spectrum based 
on their m/z.49 
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2.2 Materials 
2.2.1 Reagents/Standards 
 Sodium hydroxide, sodium carbonate, ammonium formate, formic acid, high 
performance liquid chromatography (HPLC) grade methanol, HPLC grade acetonitrile, 
and HPLC grade chloroform were purchased from Fisher Scientific Inc. (Pittsburgh, PA). 
Standards of fentanyl, fentanyl-d5, nicotine, nicotine-d4, methamphetamine, 
methamphetamine-d5, heroin, heroin-d9, cocaine, and cocaine-d3 were purchased from 
Cerilliant Corporation (Round Rock, TX). Standards of JWH-018, JWH-018-d9, JWH-081, 
and AM-2201 were purchased from Cayman Chemical Company (Ann Arbor, MI). 
Purified water was obtained by using a Direct-Q® 3 ultrapure water system from EMD 
Millipore/Merck KGaA Corporation (Darmstadt, Germany).  
The e-liquid samples (Table 1) were purchased from VaporFi® (Miami Lakes, FL), 
Mt. Baker Vapor© (Lynden, WA), Crazy Vapors© (Augusta, GA), Viking Vapor© (Ben 
Lomond, CA), and ProVape© (Monroe, WA). The e-liquid samples purchased for analysis 
were chosen to allow for as much consistency across manufacturers as possible. In order 
to allow for consistency, the specific flavors of e-liquids chosen from each manufacturer 
fell into five different “flavor categories”.  These flavor categories were tobacco, menthol, 
blueberry, vanilla, and chocolate. Three e-liquids from each flavor category were 
purchased from each manufacturer to allow for a range of nicotine concentrations from 0-
24 mg/mL. Table 1 shows all of the specific e-liquids purchased from each manufacturer 
with a total of 75 different e-liquid matrices purchased. 
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2.2.2 GC/MS Instrumentation 
 Gas chromatographic analysis was performed on an Agilent Technologies Inc. 
7890A GC System (Santa Clara, CA). Mass spectrometric analysis was performed on an 
Agilent Technologies Inc. 5975C inert XL EI/CI MSD (Santa Clara, CA). Data analysis 
was performed using Agilent MSD ChemStation software (version E.02.02.1431). 
 
2.2.3 UFLC/MS/MS Instrumentation 
 Liquid chromatographic analysis was performed on a Shimadzu Corporation Ultra-
Fast Liquid Chromatography (UFLC) system consisting of Shimadzu LC-20 AD pumps 
and a SIL-20 AC auto sampler (Kyoto, Japan). Tandem mass spectrometry analysis was 
performed on a SciexTM 4000 Qtrap (Framingham, MA). Data analysis was performed 
using Sciex Analyst® software (version 1.6.2) and quantitation was done using Sciex 
MultiQuantTM software (version 3.0.5373.0). 
 
2.3 Methods 
2.3.1 GC/MS Parameters 
 The GC/MS parameters were optimized for the detection and quantitation of 
fentanyl, nicotine, methamphetamine, cocaine, and heroin. A Restek Rxi®-5HT 
(Bellefonte, PA) column (30 m x 0.25 mm x 0.25 μm) was used for analysis. A splitless 
injection was used with an injection volume of 1 μL, an inlet temperature of 250oC, and a 
flow rate of 1.3 mL/minute (min). The oven was held at an initial temperature of 60oC for 
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two minutes, increased to 240oC at a rate of 30oC/min and then held for two minutes, 
increased to 300oC at a rate of 15oC/min and held for one minute for a total run time of 15 
minutes. The MS was operated in scan mode, using electron ionization, a solvent delay of 
four minutes, a MS quadrupole temperature of 230oC, and a MS source temperature of 
150oC. 
 
2.3.2 Sample Preparation for GC/MS Analysis 
 A liquid-liquid extraction (LLE) was performed which allowed the analytes of 
interest as well as the e-liquid matrix components to separate into the organic phase for 
analysis. Two different LLEs were utilized. One was used to identify the e-liquid matrix 
components while a separate procedure was used to quantify any drugs of abuse. When the 
goal of the analysis was to identify matrix components, 100 μL of e-liquid was pipetted 
into a disposable glass tube. This sample was then extracted by adding 1 mL of double 
deionized water (DDW), 70 μL of 10% sodium hydroxide (NaOH), and 1.5 mL of 
chloroform. The sample was then vortexed for ten seconds and 1 mL of the chloroform 
layer was pipetted into an auto sampler vial for analysis by GC/MS. 
 When the goal of analysis was to quantify drugs of abuse, 100 μL of e-liquid matrix 
was pipetted into a disposable glass tube and then spiked with a working stock solution. 
The working stock solution was prepared from standards of fentanyl, methamphetamine, 
heroin, and cocaine in methanol at a concentration of 100 μg/mL. This spiked sample was 
then extracted by adding 1 mL of DDW, 30 μL of 2% sodium carbonate (Na2CO3), and 1.5 
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mL of chloroform. This sample was then vortexed for ten seconds and 1 mL of the 
chloroform layer was pipetted into an auto sampler vial for analysis by GC/MS. 
 
2.3.3 GC/MS Method Validation 
 A six point calibration curve was generated with a range of 20-300 μg/mL for the 
analytes nicotine, methamphetamine, cocaine, heroin, and fentanyl in an e-liquid matrix 
containing 0 mg/mL of nicotine. “Unknown” samples were prepared in replicates of five 
by spiking a solution of methamphetamine, cocaine, heroin, and fentanyl at a concentration 
of 150 μg/mL into e-liquid matrix samples with a nicotine concentration of 24 mg/mL 
(Table 1).  
All samples were spiked with an internal standard solution of methamphetamine-
d5, cocaine-d3, heroin-d9, fentanyl-d5, and nicotine-d4 at a concentration of 100 μg/mL. The 
limit of detection (LOD), limit of quantitation (LOQ), coefficient of determination (R2), 
and the accuracy of the calculated “unknown” concentrations were determined using the 
ChemStation integrator available in the MSD ChemStation software. 
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Table 1: E-liquids samples analyzed. All e-liquid samples were analyzed by GC/MS to determine their 
components, samples in bold font were used for quantitative analysis by GC/MS, and samples in italic font 
were used for quantitative analysis by LC/MS/MS. 
 0 mg/mL Nicotine 
Content 
12 mg/mL Nicotine 
Content 
24 mg/mL Nicotine 
Content 
VaporFi ® 
Classic Tobacco Classic Tobacco Classic Tobacco 
Menthol Ice Menthol Ice Menthol Ice 
Blueberry Blast Blueberry Blast Blueberry Blast 
Very Vanilla Very Vanilla Very Vanilla 
Chocolate Delight Chocolate Delight Chocolate Delight 
Mt. Baker Vapor © 
East Coast Tobacco East Coast Tobacco East Coast Tobacco 
Menthol Menthol Menthol 
Blueberry Blueberry Blueberry 
French Vanilla French Vanilla French Vanilla 
Cookie Blaster Cookie Blaster Cookie Blaster 
Crazy Vapors © 
Cured Tobacco Cured Tobacco Cured Tobacco 
Menthol Menthol Menthol 
Blueberry Blueberry Blueberry 
French Vanilla French Vanilla French Vanilla 
Double Chocolate Double Chocolate Double Chocolate 
Viking Vapors © 
Tobacco Tobacco Tobacco 
Menthol Tobacco Menthol Tobacco Menthol Tobacco 
Blueberry Blueberry Blueberry 
Vanilla Vanilla Vanilla 
Chocolate Chocolate Chocolate 
ProVape © 
Ken’s Tobacco Ken’s Tobacco Ken’s Tobacco 
Icy Menthol Icy Menthol Icy Menthol 
Frosted Blueberry Frosted Blueberry Frosted Blueberry 
Simply Vanilla Simply Vanilla Simply Vanilla 
Chocolate Chocolate Chocolate 
 
 
2.3.4 LC/MS/MS Compound/Source Optimization 
 Standards of fentanyl, fentanyl-d5, methamphetamine, methamphetamine-d5, 
heroin, heroin-d9, cocaine, cocaine-d3, JWH-018, JWH-018-d9, JWH-081, and AM-2201 
were optimized in positive-ion mode, by direct infusion at a rate of 20 μL/min. The 
standards were diluted to a concentration of 10 ng/mL in a solution of 50:50 
water:methanol and the Analyst Compound Optimization software tool was used to auto 
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select the most abundant ions for use in building the final MRM method. Table 2 shows 
the final MRM table generated from the optimization procedure. 
Table 2. MRM table for LC/MS/MS analysis 
Analyte Identification 
Q1 
Mass 
(Da) 
Q3 Mass 
(Da) 
Dwell 
Time 
(msec) 
Declustering 
Potential 
(volts) 
Collision 
Energy 
(volts) 
Collision 
Cell Exit 
Potential 
(volts) 
JWH-081 1 372.092 185.100 50 91.000 35.000 14.000 
JWH-081 2 372.092 157.200 50 91.000 57.000 12.000 
JWH-018 1 342.190 155.100 50 111.000 33.000 10.000 
JWH-018 2 342.190 126.900 50 111.000 69.000 8.000 
AM-2201 1 360.127 155.100 50 106.000 37.000 14.000 
AM-2201 2 360.127 127.200 50 106.000 57.000 4.000 
Methamphetamine 1 150.065 119.300 50 51.000 15.000 10.000 
Methamphetamine 2 150.065 91.100 50 51.000 25.000 16.000 
Cocaine 1 304.107 182.200 50 51.000 27.000 14.000 
Cocaine 2 304.107 82.000 50 51.000 49.000 12.000 
Fentanyl 1 337.164 188.300 50 86.000 33.000 14.000 
Fentanyl 2 337.164 105.100 50 86.000 55.000 16.000 
Heroin 1 370.096 165.2000 50 116.000 65.000 8.000 
Heroin 2 370.096 211.000 50 116.000 43.000 10.000 
JWH-018-d9 IS 1 351.188 154.900 50 81.000 39.000 16.000 
Methamphetamine-d5 IS 1 155.089 92.200 50 51.000 27.000 6.000 
Cocaine-d3 IS 1 307.161 185.100 50 81.000 29.000 14.000 
Fentanyl-d5 IS 1 342.211 188.100 50 86.000 35.000 12.000 
Heroin-d9 IS 1 379.043 128.900 50 96.000 37.000 20.000 
 
 Once all compounds had been optimized, the ion source parameters were 
optimized. This was accomplished by incorporating flow from the LC system while 
continuing to introduce the compounds to the MS by direct infusion. The curtain gas, 
ionspray voltage, temperature, ions source gas 1, and ion source gas 2 were optimized 
during this process and the results can be seen in Table 3. 
Table 3. Optimized Ion Source Parameters 
Curtain Gas Ionspray Voltage Temperature Ion Source Gas 1 Ion Source Gas 2 
10 5000 500 70 30 
 
28 
2.3.5 LC Parameters 
 Once the compounds and source had been optimized, the LC parameters were 
optimized. The analytical column used was a 50 x 3 mm Phenomenex® (Torrance, CA) 
KinetexTM 2.6 μm C18 with TMS endcapping, and the guard column used was a 
Phenomenex® SecurityGuardTM ULTRA. The LC system was operated in binary flow with 
a flow rate of 0.5 mL/min, with mobile phase A being 2 mM ammonium formate with 0.2% 
formic acid, and mobile phase B being acetonitrile with 0.1% formic acid. The oven 
temperature was set to 40oC and the injection volume was 1 μL with the needle being 
washed before and after aspiration. The initial gradient conditions were set to 70% mobile 
phase A and 30% mobile phase B. These conditions were held for one minute before being 
changed to 5% mobile phase A and 95% mobile phase B, held for one minute and then 
changed to 95% mobile phase A and 5% mobile phase A with a final hold of two minutes 
for a total run time of six minutes. 
 
2.3.6 Sample Preparation for LC/MS/MS Analysis 
 To quantify drugs of abuse by LC/MS/MS, 100 μL of e-liquid matrix was pipetted 
into a disposable glass tube and then spiked with a working stock solution. This spiked 
sample was then extracted by adding 1 mL of DDW, 30 μL of 2% sodium carbonate 
(Na2CO3), and 1.5 mL of chloroform. This sample was then vortexed for ten seconds and 
1 mL of the chloroform layer was pipetted into a new disposable glass tube and allowed to 
evaporate to dryness. The sample was then reconstituted in 1 mL of 2 mM ammonium 
formate buffer with 0.2% formic acid and transferred to an auto sampler vial for analysis. 
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2.3.7 LC/MS/MS Method Validation 
 Two working stock solutions were prepared from standards of fentanyl, 
methamphetamine, heroin, cocaine, JWH-018, JWH-081, and AM-2201 in methanol at 
concentrations of 1 μg/mL and 100 ng/mL. An internal standard solution was prepared 
from standards of fentanyl-d5, methamphetamine-d5, heroin-d9, cocaine-d3, and JWH-018-
d9 in methanol at a concentration of 1 μg/mL. A seven point calibration curve was 
generated with a range of 20-2000 ng/mL in an e-liquid matrix. “Unknown” samples were 
prepared in replicates of five, in ten different matrices (Appendix A, Table A), and at three 
different concentrations, 40 ng/mL, 400 ng/mL, and 1500 ng/mL. Low and high quality 
control (QC) samples were prepared at concentrations of 30 ng/mL and 1600 ng/mL, 
respectively.  
The “unknown” samples were evaluated over the course of three different runs with 
a new calibration curve being prepared for each run.  Additionally, a low and high QC 
sample was injected every ten samples within each run. The bias, within-run precision, 
between-run precision, carryover, LOD, LOQ, and R2 were evaluated for each analyte in 
the ten different e-liquid matrices. 
  
30 
3. RESULTS  
3.1 GC/MS Qualitative Results 
 The e-liquid samples were evaluated by GC/MS to determine the components of 
the e-liquid matrix and over 40 different compounds were detected in addition to the 
manufacturer stated nicotine and propylene glycol. Tables 4-8 shows the flavorants that 
were detected in each e-liquid sample by flavor category. 
Table 4: Detected E-liquid Flavorants: Flavorants detected in the tobacco flavor category e-liquid samples. 
Identification of flavorants was made by comparing the mass spectrum of the suspected flavorant to mass 
spectra from the NIST library. 
E-liquid Sample Flavorant Compounds 
VaporFi Classic 
Tobacco 
Cinnamic acid, methylester; β-damascone 
Mt. Baker Vapor East 
Coast Tobacco 
Trimethyl pyrazine; tetramethyl pyrazine; menthol; β-citronellol; guaniol 
Crazy Vapors Cured 
Tobacco 
Trimethyl pyrazine; tetramethyl pyrazine; gluethimide 
Viking Vapor 
Tobacco 
Piperonal 
ProVape Ken’s 
Tobacco 
Benzophenone; tetramethyl pyrazine; menthol; guaniol; cinnamaldehyde 
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Table 5: Detected E-liquid Flavorants: Flavorants detected in the menthol flavor category e-liquid samples. 
Identification of flavorants was made by comparing the mass spectrum of the suspected flavorant to mass 
spectra from the NIST library. 
E-liquid Sample Flavorant Compounds 
VaporFi Menthol Ice Eucalyptol; menthol 
Mt. Baker Vapor 
Menthol 
Menthol 
Crazy Vapors 
Menthol 
Menthol 
Viking Vapors 
Menthol Tobacco 
Menthol; piperonal; benzyl benzoate 
ProVape Icy Menthol Benzyl alcohol; menthol; cinnamaldehyde; benzophenone 
 
 
Table 6: Detected E-liquid Flavorants: Flavorants detected in the blueberry flavor category e-liquid 
samples. Identification of flavorants was made by comparing the mass spectrum of the suspected flavorant 
to mass spectra from the NIST library. 
E-liquid Sample Flavorant Compounds 
VaporFi Blueberry 
Blast 
Benzyl alcohol; β-linalool; menthol; cis-geraniol; β-damascenone; davanone 
Mt. Baker Vapor 
Blueberry 
Benzyl alcohol; tetramethyl pyrazine; β-linalool; menthol; benzophenone 
Crazy Vapors 
Blueberry 
β-linalool; cis-jasmone; glutethimide 
Viking Vapors 
Blueberry 
Benzyl alcohol; β-linalool 
ProVape Frosted 
Blueberry 
Benzyl alcohol; β-linalool; benzophenone 
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Table 7: Detected E-liquid Flavorants: Flavorants detected in the vanilla flavor category e-liquid samples. 
Identification of flavorants was made by comparing the mass spectrum of the suspected flavorant to mass 
spectra from the NIST library. 
E-liquid Sample Flavorant Compounds 
VaporFi Very Vanilla Anethole; piperonal 
Mt. Baker Vapor 
French Vanilla 
Piperonal 
Crazy Vapors French 
Vanilla 
4-methoxy-benzaldehyde 
Viking Vapors Vanilla 
Butanoic acid; 3-methyl-3-methylbutylester (apple oil); butyl butyryl lactate; 
vanillin 
ProVape Simply 
Vanilla 
Anise alcohol; vanillin; benzophenone 
 
 
Table 8: Detected E-liquid Flavorants: Flavorants detected in the chocolate flavor category e-liquid 
samples. Identification of flavorants was made by comparing the mass spectrum of the suspected flavorant 
to mass spectra from the NIST library. 
E-liquid Sample Flavorant Compounds 
VaporFi Chocolate 
Delight 
Benzyl alcohol 
Mt. Baker Vapor 
Cookie Blaster 
Menthol; piperonal; benzophenone 
Crazy Vapors Double 
Chocolate 
Trimethyl pyrazine; benzyl alcohol; tetramethyl pyrazine; glutethimide 
Viking Vapors 
Chocolate 
Trimethyl pyrazine; tetramethyl pyrazine 
ProVape Chocolate 
Trimethyl pyrazine; benzyl alcohol; tetramethyl pyrazine; piperonal; benzyl 
benzoate 
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3.2 GC/MS Quantitative Results 
 A six point calibration curve was generated over the range of 20 μg/mL-300 μg/mL 
and used to determine the LOD, LOQ, and the R2 value for each target analyte, 
methamphetamine, cocaine, nicotine, heroin, and fentanyl.  Figure 3 shows a combined 
calibration curve for the analytes nicotine, cocaine, heroin, and fentanyl. 
Methamphetamine was unable to be quantified due to interference from the e-liquid matrix. 
Figure 3: Calibration curve of nicotine, cocaine, heroin, and fentanyl. Of the six points generated for use 
in the calibration curve five were used, with the sixth point falling below the LOQ. The R2 value for each 
analyte fell above the acceptable limit of 0.98. 
 
 From the generated calibration curve it was determined that the LOD for this 
instrument and method was 1 μg/mL, and the LOQ was 30 μg/mL, due to the fact that the 
lowest calibration point (20 μg/mL) was unable to be integrated by the software and 
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therefore unable to be quantified for all target analytes. The R2 values for each of the 
analytes able to be quantified all fell above the acceptable value of 0.98 with the R2 value 
for nicotine being 0.9975, for cocaine being 0.9955, for heroin being 0.9971, and for 
fentanyl being 0.9879. 
 The accuracy of the “unknown” samples was determined by comparing the 
calculated concentration of each analytes to the target concentration of 150 μg/mL. An 
accuracy of greater than ±20% was considered to be inaccurate. The results of the accuracy 
calculations can be seen in Table 9. 
Table 9: Calculated Concentrations of “Unknown” Samples. The range of concentrations for each analyte 
in each matrix is shown with the average value being shown in parentheses ( ). Calculated concentrations 
that fell outside of the ±20% of 150 μg/mL range (cocaine, heroin, and fentanyl) and 24 mg/mL (nicotine) 
are in bold and italic font. 
 
Nicotine 
(mg/mL) 
Cocaine 
(μg/mL) 
Heroin 
(μg/mL) 
Fentanyl 
(μg/mL) 
VaporFi Classic Tobacco 
29.38-30.26 
(29.98) 
134.2-142.1 
(141.1) 
133.9-138.8 
(135.5) 
156.0-168.1 
(170.9) 
VaporFi Menthol Ice 
26.46-29.92 
(28.38) 
119.9-138.3 
(127.8) 
84.25-99.69 
(90.36) 
153.2-178.8 
(164.1) 
VaporFi Blueberry Blast 
25.67-28.54 
(26.45) 
103.9-116.8 
(111.2) 
126.9-145.6 
(136.3) 
141.2-153.5 
(149.4) 
VaporFi Very Vanilla 
26.23-27.56 
(27.09) 
119.3-126.9 
(124.1) 
122.6-132.9 
(127.8) 
152.8-158.9 
(155.1) 
VaporFi Chocolate 
Delight 
25.20-25.92 
(25.53) 
103.9-118.5 
(111.8) 
113.8-136.3 
(126.3) 
147.7-154.9 
(151.7) 
Mt. Baker Vapor East 
Coast Tobacco 
26.05-29.54 
(26.88) 
113.8-135.2 
(116.7) 
129.3-151.2 
(131.3) 
151.9-165.2 
(149.3) 
Mt. Baker Vapor Menthol 
32.24-32.65 
(32.39) 
132.8-141.7 
(137.5) 
111.3-126.8 
(120.1) 
179.2-211.8 
(199.7) 
Mt. Baker Vapor 
Blueberry 
27.43-30.25 
(29.09) 
111.9-127.8 
(118.8) 
101.4-114.7 
(106.3) 
150.8-161.4 
(156.2) 
Mt. Baker Vapor French 
Vanilla 
24.07-27.61 
(26.46) 
94.46-118.6 
(109.2) 
105.5-133.7 
(124.4) 
120.2-151.0 
(137.9) 
Mt. Baker Vapor Cookie 
Blaster 
20.39-21.78 
(21.14) 
68.53-77.59 
(73.33) 
71.51-83.39 
(77.65) 
75.70-98.71 
(87.07) 
Crazy Vapors Cured 
Tobacco 
10.82-12.01 
(11.58) 
133.2-139.7 
(135.1) 
121.0-126.3 
(122.4) 
101.4-104.1 
(102.5) 
Crazy Vapors Menthol 
8.33-8.53 
(8.46) 
102.3-112.7 
(108.3) 
124.1-131.6 
(128.2) 
84.58-92.57 
(88.28) 
Crazy Vapors Blueberry 
9.28-10.19 
(9.59) 
133.3-144.1 
(138.9) 
119.2-131.4 
(125.8) 
115.6-123.6 
(119.2) 
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Nicotine 
(mg/mL) 
Cocaine 
(μg/mL) 
Heroin 
(μg/mL) 
Fentanyl 
(μg/mL) 
Crazy Vapors French 
Vanilla 
8.49-9.44 
(9.10) 
155.5-167.2 
(162.1) 
177.8-184.7 
(181.3) 
167.9-174.9 
(171.8) 
Crazy Vapors Double 
Chocolate 
9.03-10.19 
(9.65) 
147.8-164.5 
(156.5) 
161.3-178.6 
(170.5) 
128.5-144.7 
(142.9) 
Viking Vapors Tobacco 
11.35-12.29 
(11.72) 
102.2-104.9 
(103.9) 
122.7-129.3 
(126.4) 
63.31-72.07 
(68.19) 
Viking Vapors Menthol 
Tobacco 
12.50-13.16 
(12.81) 
117.6-126.2 
(120.5) 
130.4-140.8 
(136.6) 
93.16-99.52 
(96.51) 
Viking Vapors Blueberry 
12.75-13.66 
(13.21) 
143.5-145.5 
(143.6) 
121.2-125.5 
(123.3) 
116.0-126.6 
(123.3) 
Viking Vapors Vanilla 
12.27-13.62 
(12.77) 
171.1-176.2 
(174.3) 
193.7-197.9 
(195.7) 
170.1-182.3 
(177.1) 
Viking Vapors Chocolate 
13.16-14.07 
(13.54) 
150.7-159.9 
(154.5) 
160.6-164.9 
(162.6) 
125.3-131.9 
(128.3) 
ProVape Ken’s Tobacco 
17.61-18.20 
(18.02) 
150.7-156.6 
(153.8) 
138.1-145.0 
(142.5) 
134.4-141.3 
(138.9) 
ProVape Icy Menthol 
15.56-16.45 
(15.95) 
152.7-158.1 
(154.9) 
150.4-154.6 
(151.8) 
170.8-176.3 
(173.4) 
ProVape Frosted 
Blueberry 
16.39-18.15 
(17.16) 
138.6-146.9 
(143.9) 
117.8-136.9 
(127.6) 
117.9-124.8 
(120.4) 
ProVape Simply Vanilla 
14.86-15.18 
(14.99) 
169.9-177.8 
(174.6) 
177.1-192.7 
(183.9) 
188.3-199.3 
(194.9) 
ProVape Chocolate 
15.10-16.39 
(15.63) 
156.3-161.9 
(160.1) 
165.5-171.2 
(168.1) 
100.2-104.8 
(102.6) 
 
 
Twenty-five of the 75 e-liquid samples analyzed were stated by manufacturers to 
contain 0 mg/mL of nicotine. Of those 25 samples six contained no detectable nicotine, 
five contained detectable levels of nicotine that fell below the LOQ, and 14 contained 
detectable and quantifiable concentrations of nicotine. A t-test was conducted to 
determine if there was a statistical difference between the levels of nicotine in the 14 e-
liquid sample compared to nicotine containing food products (i.e. eggplant).  A mean 
concentration of 0.1 µg/mL was found in eggplant samples and was used in the t-test 
calculations.51 The results of the t-tests can be seen in Table 10. 
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Table 10: T-Test Results. For all 14 samples the null hypothesis was rejected and it was found that there 
was a statistical difference between the levels of nicotine found naturally in eggplant to those found in the 
e-liquid samples. 
 
Average Nicotine 
Concentration 
(µg/mL) 
tcalc tcritical H0 
Mt. Baker Vapor 
East Coast 
Tobacco 
96.33 50.69 2.78 X 
Mt. Baker Vapor 
Menthol 
52.69 95.42 2.78 X 
Mt. Baker Vapor 
Blueberry 
215.65 36.96 2.78 X 
Mt. Baker Vapor 
French Vanilla 
415.58 57.37 2.78 X 
Mt. Baker Vapor 
Cookie Blaster 
171.47 22.10 2.78 X 
Crazy Vapors 
Cured Tobacco 
31.92 39.98 2.78 X 
Crazy Vapors 
Menthol 
90.79 39.60 2.78 X 
Crazy Vapors 
Blueberry 
51.21 14.87 2.78 X 
Crazy Vapors 
Double Chocolate 
193.2 4.55 2.78 X 
ProVape Ken’s 
Tobacco 
45.36 27.26 2.78 X 
ProVape Icy 
Menthol 
58.92 74.94 2.78 X 
ProVape Frosted 
Blueberry 
32.13 40.81 2.78 X 
ProVape Simply 
Vanilla 
62.67 144.1 2.78 X 
ProVape 
Chocolate 
71.08 76.03 2.78 X 
 
 
3.3 LC/MS/MS Quantitative Results 
 Seven point calibration curves were generated over the course of six runs with a 
range of 20 ng/mL - 2000 ng/mL and used to determine the LOD, LOQ, quantifiable 
carryover, and the R2 value for each target analyte, methamphetamine, cocaine, heroin, 
37 
fentanyl, JWH-081, JWH-018, and AM-2201.  Figure 4 shows a combined calibration 
curve for the analytes methamphetamine, cocaine, heroin, fentanyl, JWH-081, JWH-018, 
and AM-2201.  
From the generated calibration curves it was determined that the LOQ was 20 
ng/mL due to the fact that all calibrators and quality control samples were able to be 
accurately included in the range. The LOD was determined to be 10 ng/mL due to the fact 
that at lower concentrations some analytes (heroin, JWH-018, and JWH-081) were unable 
to be differentiated from the background noise. No quantifiable carryover was observed 
for any analyte after the highest calibrator, which was at a concentration of 2000 ng/mL. 
The R2 value for each analyte was above the acceptable limit of 0.98 with the average R2 
value for methamphetamine being 0.99409, for cocaine being 0.99793, for heroin being 
0.99285, for fentanyl being 0.9988, for JWH-081 being 0.99292, for JWH-018 being 
0.99661, and for AM-2201 being 0.99509. 
 The “unknown” samples were analyzed to determine accuracy, precision within 
each run, and the precision between runs for each of the seven analytes across all ten e-
liquid matrices. Table 11 shows the range and mean calculated concentration determined 
by LC/MS/MS analysis for all “unknown” samples that were spiked at a concentration of 
40 ng/mL. Of the 70 calculated concentrations, 24 fell outside the acceptable accuracy 
range. 
Table 12 shows the range and mean calculated concentration determined by 
LC/MS/MS analysis for all “unknown” samples that were spiked at a concentration of 400 
ng/mL. Of the 70 calculated concentrations, 14 fell outside the acceptable accuracy range. 
38 
Table 13 shows the range and mean calculated concentration determined by 
LC/MS/MS analysis for all “unknown” samples that were spiked at a concentration of 1500 
ng/mL. Of the 70 calculated concentrations, 17 fell outside the acceptable accuracy range.  
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Table 11: Calculated Concentrations of “Unknown” Samples. The range of concentrations for each 
analyte in each matrix is shown with the average value being shown in parentheses ( ). Calculated 
concentrations that fell outside of the ±20% accuracy of 40 ng/mL range are in bold and italic font. 
 JWH-081 JWH-018 AM-2201 
Methamp-
hetamine 
Cocaine Fentanyl Heroin 
VaporFi 
Menthol 
Ice 
22.7-43.1 
(34.0) 
25.1-34.9 
(28.4) 
22.9-42.2 
(30.4) 
30.2-58.0 
(40.9) 
36.1-45.6 
(40.0) 
33.8-47.8 
(39.2) 
11.2-28.7 
(22.1) 
VaporFi 
Very 
Vanilla 
33.9-52.7 
(38.6) 
17.7-38.7 
(29.2) 
7.67-63.7 
(38.3) 
26.3-53.6 
(39.3) 
37.2-46.9 
(42.1) 
29.8-45.2 
(38.6) 
30.7-47.5 
(36.5) 
Mt. 
Baker 
Vapors 
East 
Coast 
Tobacco 
3.23-35.6 
(20.2) 
15.2-29.3 
(20.7) 
43.4-
105.8 
(74.7) 
25.1-44.9 
(32.4) 
33.9-45.1 
(38.8) 
30.1-44.6 
(38.1) 
22.4-46.4 
(35.4) 
Mt. 
Baker 
Vapors 
Menthol 
26.5-
126.7 
(62.2) 
13.6-42.7 
(29.3) 
17.9-51.0 
(39.9) 
27.9-51.5 
(37.9) 
35.3-45.9 
(39.7) 
34.4-44.2 
(38.1) 
18.4-62.9 
(34.9) 
Crazy 
Vapors 
Menthol 
41.5-49.5 
(44.4) 
33.2-49.5 
(42.8) 
50.0-53.9 
(51.5) 
16.0-42.7 
(30.2) 
32.5-44.4 
(38.9) 
32.2-46.7 
(39.4) 
39.7-89.9 
(61.8) 
Crazy 
Vapors 
French 
Vanilla 
30.5-47.7 
(38.6) 
19.2-54.5 
(38.6) 
43.3-91.3 
(70.1) 
16.7-41.6 
(31.8) 
32.9-41.9 
(37.8) 
30.9-47.3 
(37.7) 
18.9-47.7 
(36.8) 
Viking 
Vapors 
Menthol 
Tobacco 
36.1-48.0 
(43.7) 
40.4-49.6 
(45.7) 
15.1-50.8 
(34.4) 
27.3-46.6 
(36.2) 
35.6-45.4 
(41.2) 
34.1-44.4 
(39.6) 
51.2-
104.9 
(74.2) 
Viking 
Vapors 
Vanilla 
26.6-53.1 
(38.8) 
32.3-46.7 
(39.8) 
31.4-58.8 
(41.0) 
19.1-37.8 
(29.8) 
33.3-47.1 
(40.4) 
29.3-42.8 
(35.8) 
48.9-
109.1 
(87.3) 
ProVape 
Icy 
Menthol 
41.1-70.8 
(55.2) 
41.2-51.2 
(46.0) 
23.7-38.8 
(29.8) 
11.5-48.8 
(34.5) 
34.7-43.2 
(38.7) 
28.3-43.9 
(37.1) 
9.2-26.9 
(16.6) 
ProVape 
Simply 
Vanilla 
53.2-94.9 
(69.5) 
34.2-48.3 
(41.5) 
14.2-23.0 
(18.8) 
13.8-43.3 
(31.3) 
33.0-42.9 
(37.2) 
28.4-42.4 
(34.2) 
30.2-98.8 
(64.2) 
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Table 12: Calculated Concentrations of “Unknown” Samples. The range of concentrations for each 
analyte in each matrix is shown with the average value being shown in parentheses ( ). Calculated 
concentrations that fell outside of the ±20% accuracy of 400 ng/mL range are in bold and italic font. 
 JWH-081 JWH-018 AM-2201 
Methamp-
hetamine 
Cocaine Fentanyl Heroin 
VaporFi 
Menthol 
Ice 
320.9-
458.8 
(375.7) 
338.3-
439.4 
(391.7) 
330.5-
565.1 
(463.5) 
338.4-
478.4 
(415.2) 
374.9-
441.2 
(413.4) 
331.1-
472.1 
(407.2) 
314.6-
399.1 
(349.7) 
VaporFi 
Very 
Vanilla 
294.9-
495.4 
(381.4) 
368.7-
468.6 
(434.4) 
359.2-
655.5 
(524.2) 
322.4-
448.6 
(387.3) 
356.4-
444.0 
(403.4) 
353.3-
465.6 
(402.6) 
354.1-
437.2 
(387.9) 
Mt. 
Baker 
Vapors 
East 
Coast 
Tobacco 
246.1-
427.1 
(328.9) 
379.2-
479.2 
(438.3) 
706.4-
1221.6 
(943.7) 
240.4-
472.5 
(370.4) 
343.9-
449.9 
(406.9) 
350.2-
471.2 
(408.2) 
398.4-
578.2 
(480.8) 
Mt. 
Baker 
Vapors 
Menthol 
301.7-
525.8 
(412.3) 
344.6-
474.7 
(423.5) 
322.4-
549.9 
(418.4) 
312.2-
473.0 
(398.1) 
369.2-
475.9 
(423.9) 
357.9-
477.4 
(397.9) 
303.9-
518.2 
(402.9) 
Crazy 
Vapors 
Menthol 
300.3-
463.2 
(370.0) 
310.3-
461.0 
(374.5) 
290.7-
464.8 
(385.1) 
274.3-
462.5 
(340.4) 
354.9-
476.1 
(411.5) 
354.7-
461.3 
(404.7) 
586.0-
889.8 
(754.7) 
Crazy 
Vapors 
French 
Vanilla 
210.3-
416.1 
(304.9) 
304.4-
371.1 
(343.5) 
521.1-
1001.4 
(800.371) 
290.2-
471.1 
(359.1) 
373.9-
474.5 
(414.4) 
366.5-
428.6 
(402.8) 
465.4-
675.5 
(574.5) 
Viking 
Vapors 
Menthol 
Tobacco 
354.3-
477.0 
(421.6) 
317.1-
474.5 
(412.4) 
236.6-
481.4 
(365.7) 
364.4-
495.5 
(421.4) 
388.9-
477.7 
(427.6) 
360.9-
472.8 
(419.2) 
677.0-
985.4 
(820.4) 
Viking 
Vapors 
Vanilla 
260.1-
467.9 
(381.9) 
282.6-
470.1 
(353.4) 
277.6-
488.3 
(378.7) 
321.9-
444.3 
(380.1) 
373.5-
466.3 
(418.7) 
324.9-
475.5 
(419.4) 
719.3-
1534.6 
(1072.4) 
ProVape 
Icy 
Menthol 
240.3-
572.5 
(426.2) 
304.2-
469.4 
(392.4) 
323.6-
474.9 
(374.4) 
122.0-
457.8 
(301.7) 
353.5-
466.8 
(421.9) 
373.7-
476.4 
(408.1) 
285.1-
386.2 
(349.7) 
ProVape 
Simply 
Vanilla 
436.5-
797.5 
(590.0) 
320.0-
435.7 
(383.6) 
261.7-
355.6 
(294.0) 
246.4-
472.9 
(344.5) 
336.9-
434.2 
(398.5) 
351.3-
458.5 
(393.7) 
746.9-
1051.1 
(875.6) 
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Table 13: Calculated Concentrations of “Unknown” Samples. The range of concentrations for each 
analyte in each matrix is shown with the average value being shown in parentheses ( ). Calculated 
concentrations that fell outside of the ±20% accuracy of 1500 ng/mL range are in bold and italic font. 
 JWH-081 JWH-018 AM-2201 
Methamp-
hetamine 
Cocaine Fentanyl Heroin 
VaporFi 
Menthol 
Ice 
1267.3-
1607.2 
(1467.1) 
1570.6-
1727.6 
(1648.1) 
1459.9-
2946.7 
(1997.6) 
1011.3-
1497.0 
(1307.4) 
1432.4-
1639.9 
(1526.3) 
1333.7-
1750.7 
(1488.3) 
740.0-
1156.2 
(979.5) 
VaporFi 
Very 
Vanilla 
1153.7-
1805.3 
(1472.4) 
1559.7-
1750.1 
(1660.9) 
1299.9-
2828.6 
(2100.8) 
1015.9-
1613.2 
(1367.7) 
1415.5-
1709.7 
(1530.8) 
1261.6-
1755.1 
(1472.5) 
1308.8-
1519.1 
(1424.6) 
Mt. 
Baker 
Vapors 
East 
Coast 
Tobacco 
822.6-
1565.7 
(1110.8) 
1266.5-
1898.4 
(1617.3) 
2259.3-
4250.8 
(2990.2) 
949.7-
1593.9 
(1245.3) 
1379.1-
1577.5 
(1482.8) 
1234.5-
1692.5 
(1438.2) 
1423.5-
1799.9 
(1599.2) 
Mt. 
Baker 
Vapors 
Menthol 
980.4-
2046.1 
(1433.1) 
1335.3-
1786.9 
(1572.6) 
1418.3-
2066.2 
(1699.6) 
1015.4-
1789.7 
(1386.8) 
1277.9-
1639.4 
(1496.3) 
1333.2-
1752.7 
(1508.7) 
1021.8-
1386.5 
(1183.9) 
Crazy 
Vapors 
Menthol 
1267.3-
1792.0 
(1569.3) 
1223.0-
1638.0 
(1436.8) 
1443.2-
1790.8 
(1668.6) 
1103.3-
1583.0 
(1277.1) 
1385.3-
1713.0 
(1525.5) 
1391.9-
1651.0 
(1518.6) 
1665.8-
2881.5 
(2285.5) 
Crazy 
Vapors 
French 
Vanilla 
640.3-
1477.4 
(984.0) 
1195.4-
1675.6 
(1407.6) 
2463.8-
4040.7 
(3162.7) 
936.3-
1754.3 
(1237.5) 
1280.8-
1679.3 
(1468.5) 
1342.9-
1614.3 
(1488.1) 
1944.0-
2543.9 
(2160.3) 
Viking 
Vapors 
Menthol 
Tobacco 
1319.8-
1956.5 
(1654.2) 
1095.6-
1630.3 
(1382.9) 
860.3-
1540.3 
(1254.1) 
1326.9-
1648.1 
(1471.7) 
1319.8-
1709.6 
(1555.4) 
1474.5-
1891.7 
(1672.2) 
2293.3-
3812.7 
(2853.2) 
Viking 
Vapors 
Vanilla 
896.3-
1540.3 
(1175.4) 
944.3-
1361.7 
(1126.1) 
1350.9-
1808.1 
(1585.8) 
1129.8-
1515.1 
(1377.1) 
1333.2-
1646.9 
(1517.2) 
1316.9-
1766.7 
(1575.5) 
2211.0-
4334.7 
(3326.7) 
ProVape 
Icy 
Menthol 
1015.6-
2307.8 
(1634.7) 
1247.7-
1788.5 
(1523.3) 
1056.3-
1748.1 
(1369.3) 
807.9-
1557.0 
(1235.5) 
1383.2-
1711.7 
(1532.9) 
1270.1-
1695.2 
(1484.2) 
775.7-
1384.1 
(1101.3) 
ProVape 
Simply 
Vanilla 
1412.4-
1749.9 
(1630.6) 
1176.8-
1704.3 
(1420.4) 
712.9-
1328.5 
(1151.6) 
937.6-
1729.8 
(1250.9) 
1374.2-
1722.3 
(1532.8) 
1410.3-
1683.9 
(1518.9) 
2231.6-
3548.2 
(2867.6) 
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 Accuracy of the “unknown” samples was calculated for each of the seven analytes, 
at each of the three concentrations, across all ten e-liquid matrices using the following 
equation. 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) = [
𝐺𝑟𝑎𝑛𝑑 𝑀𝑒𝑎𝑛 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
] 𝑥 100 
 
Precision of the “unknown” samples was calculated for each of the seven analytes, 
at each of the three concentrations, across all ten e-liquid matrices, for each of the three 
runs, and between the three runs using the following equations. 
𝑊𝑖𝑡ℎ𝑖𝑛 − 𝑟𝑢𝑛 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%) = [
𝑠𝑡𝑑. 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
] 𝑥100 
 
𝐵𝑒𝑡𝑤𝑒𝑒𝑛 − 𝑟𝑢𝑛 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%) = [
𝑠𝑡𝑑. 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛
𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛
] 𝑥100 
 Table 14 shows the results of the accuracy and precision calculations for all three 
concentrations of “unknown” samples for the Mt. Baker Vapors Menthol e-liquid matrix. 
No calculations were made for the JWH-018 analyte at any concentration during run 
three due to contamination in the LC/MS/MS system. The results of the accuracy and 
precision calculations for the remaining e-liquid matrices can be found in Appendix A, 
Tables A-I. 
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Table 14: Accuracy and Precision Results for Mt. Baker Vapors Menthol. The maximum acceptable 
percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range 
are in bold and italic font. 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
62.2 55.5 11.4 9.71 11.5 61.2 
JWH-081 (400 
ng/mL) 
412.3 3.07 11.2 15.2 9.66 14.2 
JWH-081 (1500 
ng/mL) 
1433.2 -4.46 6.66 8.29 8.19 23.8 
JWH-018 (40 
ng/mL) 
29.3 -26.8 7.03 21.6 N/A 32.3 
JWH-018 (400 
ng/mL) 
423.5 5.88 5.75 9.03 N/A 9.04 
JWH-018 (1500 
ng/mL) 
1572.6 4.84 1.76 6.32 N/A 10.8 
AM-2201 (40 
ng/mL) 
37.6 -5.98 2.82 42.0 19.1 32.4 
AM-2201 (400 
ng/mL) 
418.4 4.59 15.9 8.85 11.7 15.6 
AM-2201 (1500 
ng/mL) 
1699.6 13.3 15.6 3.79 4.32 9.69 
Methamphetamine 
(40 ng/mL) 
37.9 -5.04 8.65 7.23 14.5 18.9 
Methamphetamine 
(400 ng/mL) 
398.1 -0.49 1.43 8.36 5.45 13.9 
Methamphetamine 
(1500 ng/mL) 
1386.8 -7.54 6.96 7.22 8.22 17.1 
Cocaine (40 
ng/mL) 
39.72 -0.69 8.42 4.03 7.27 8.21 
Cocaine (400 
ng/mL) 
423.95 5.98 4.87 5.13 9.00 7.42 
Cocaine (1500 
ng/mL) 
1496.3 -0.25 4.86 4.57 8.22 6.76 
Fentanyl (40 
ng/mL) 
38.08 -4.80 6.18 4.92 1.75 7.32 
Fentanyl (400 
ng/mL) 
397.9 -0.51 5.63 2.97 4.99 8.48 
Fentanyl (1500 
ng/mL) 
1508.7 0.58 3.64 3.81 4.19 8.97 
Heroin (40  
ng/mL) 
34.95 -12.62 15.05 37.38 25.26 37.9 
Heroin (400 
ng/mL) 
402.9 0.72 13.02 12.16 10.36 16.31 
Heroin (1500 
ng/mL) 
1183.9 -21.08 8.49 10.35 6.16 8.57 
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4. DISCUSSION 
4.1 GC/MS Analysis 
4.1.1 E-liquid Components 
 Manufacturers of e-liquids typically list only propylene glycol, vegetable glycerin, 
and nicotine as ingredients and leave out all of the specific natural and artificial flavorants 
used. Analysis by GC/MS to determine the flavorants used in these e-liquids detected over 
40 different compounds in addition to propylene glycol and nicotine. Vegetable glycerin 
was not detected in any of the samples, but was present in all samples according to the 
manufacturer’s labels. The vegetable glycerin may not have been detected because its 
concentration was very low compared with the other components, or this may have been a 
limitation of the method. Tables 4-8 show the compounds that were detected in the e-
liquids. Of the flavorants listed almost all of them are approved by the FDA for use as 
additives in food.52 However, one compound, glutethimide, which was detected in all of 
the Crazy Vapors Double Chocolate, Crazy Vapors Cured Tobacco, and Crazy Vapors 
Blueberry e-liquids, is a Schedule II substance controlled by the DEA.52 
 While glutethimide was only detected in nine of the 75 e-liquid matrices, it was the 
fourth most abundant peak in those matrices. Detection of this flavorant provides just one 
of several reasons why e-liquids may need stricter regulations applied to them. Currently, 
manufacturers are not responsible for following any regulations in the preparation of their 
e-liquids.6 One manufacturer, VaporFi, claims to use only FDA approved ingredients but 
this is not a requirement or the norm.7  
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 Even though there are no regulations surrounding e-liquids, some manufacturers 
have removed certain flavorants that have been shown to cause damage to the airway when 
inhaled. According to the Centers for Disease Control and Prevention (CDC), diacetyl, 
which is commonly used to give microwave popcorn its butter flavor, has been shown to 
cause damage to the airways in animals during toxicology studies. Diacetyl has been used 
in e-liquid flavors that have a creamy or buttery flavor; however, many manufacturers no 
longer use this flavorant and make a point to state so on their web pages. 
 The flavorants detected in the e-liquid matrices that are approved by the FDA still 
may not be safe to use as additives in e-liquids. Those flavorants are approved by the FDA 
for use as additives in food to be consumed orally.52 In e-cigarettes, however, those 
compounds are vaporized and inhaled. There is little published data on the effects that 
inhalation of those compounds has on the human body. Further research needs to be 
conducted involving these flavorants to determine their toxicity by vaporization and 
inhalation before they can be deemed safe to use in e-liquids. 
 In addition to detecting over 40 compounds in the e-liquid matrices tested, it was 
observed that there was little consistency between similar flavors from different 
manufacturers. The greatest consistency between manufacturers was observed in the 
menthol flavor category. Menthol was detected in e-liquids from all five manufacturers in 
the menthol flavor category, however, menthol was also detected by at least one 
manufacturer in the tobacco, blueberry, and chocolate flavor categories (Tables 4-8). With 
the exception of menthol, there is little consistency in the flavorants used by different 
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manufacturers within the same flavor category and even between different flavor categories 
within the same manufacturer.  
There is also no discernable pattern for certain flavorants used by multiple 
manufacturers. For example, piperonal is used in four of the five different flavor categories. 
It is used by Viking Vapors in their tobacco and menthol flavors but not in blueberry, 
vanilla, or chocolate flavors. However, Mt. Baker Vapors used piperonal in their vanilla 
and chocolate flavors but not in their tobacco, menthol, or blueberry flavors. This lack of 
consistency within flavor categories, and within manufacturers makes it impossible for 
users to determine what is actually in the product they are consuming. 
 
4.1.2 Liquid-Liquid Extractions 
 Two different liquid-liquid extractions (LLE) were performed for analysis by 
GC/MS. In the LLE to determine the components of the e-liquid matrices a 10% NaOH 
base was used and in the LLE to quantify the drugs of abuse added to the e-liquid matrix a 
2% Na2CO3 base was used. This difference was necessary to prevent the extraction used 
for quantitation from becoming too basic in pH causing the heroin to degrade. However, it 
was noted that the two different extractions provided different chromatograms of the same 
sample as seen in Figure 5. 
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Figure  5. Differences in liquid-liquid extractions. Top: Liquid-liquid extraction using 2% sodium 
carbonate as the base, Bottom: Liquid-liquid extraction using 10% sodium hydroxide as the base. The 10% 
sodium hydroxide allows more information to be gathered about the e-liquid sample, however, the 2% sodium 
carbonate is necessary to use for successful quantitation of heroin. 
 
 The LLE utilizing 10% NaOH provided more information regarding the 
components of the e-liquid matrix when compared to the 2% Na2CO3. It is possible that 
the use of a third base may provide an even greater amount of information regarding the 
components of the e-liquid matrices than either of these two methods. 
 
4.1.3 Qualitative Analysis of Spiked Samples 
All of the spiked e-liquid samples were prepared in a matrix that was stated by the 
manufacturer to contain 24 mg/mL of nicotine. This resulted in a nicotine peak of such a 
high abundance that it masked nearly every other component of the e-liquid matrix, 
including the drugs of abuse. The nicotine peak was so abundant that the spiked e-liquid 
sample chromatogram was nearly identical to the unspiked e-liquid chromatogram. 
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However, when the nicotine peak was ignored and the chromatogram was zoomed in along 
the baseline, the peaks of the spiked drugs of abuse were observed as seen in Figure 6. 
Figure  6. Chromatograms of the VaporFi Very Vanilla e-liquid. Top: unspiked VaporFi Very Vanilla 
sample, Middle: spiked VaporFi Very Vanilla sample, Bottom: spiked VaporFi Very Vanilla sample zoomed 
in to show peaks of drugs of abuse used for quantitation. 
 
 
 These chromatograms demonstrate the importance of knowing the retention times 
of common drugs of abuse that may be added to e-liquids. For the method used in this 
analysis the retention time of cocaine is 10.451 minutes, heroin is 13.261 minutes, and 
fentanyl is 13.701 minutes. While the peaks for the drugs of abuse spiked into the e-liquid 
sample are much lower in abundance when compared to the nicotine peak, they were still 
able to be recognized and integrated by the ChemStation integrator. This demonstrates that 
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if the retention times of common drugs of abuse are not known it is possible that they may 
be missed by an analyst in routine casework. 
 Another possible issue with the qualitative analysis of spiked e-liquid samples is 
interference from the e-liquid matrix masking drugs of abuse. In this study the retention 
time of methamphetamine (5.530 minutes) was very similar to both menthol (5.490 
minutes) and ethyl maltol (5.587 minutes). This resulted in a lack of resolution of 
methamphetamine and detection until reaching a concentration of over 100 μg/mL. Figure 
7 shows the methamphetamine peak in a spiked VaporFi Very Vanilla sample. In this 
chromatogram it can be seen that the methamphetamine peak is just barely resolved from 
the ethyl maltol peak and if the baseline is zoomed in it is possible to see that the two peaks 
are not completely resolved. 
Figure  7. Chromatograms of the VaporFi Very Vanilla e-liquid. This chromatogram shows that the 
methamphetamine peak is unable to be completely resolved from the e-liquid component ethyl maltol.  
 
 This interference issue indicates a need to further optimize the extraction technique 
and/or the GC/MS parameters to allow for better resolution of the peaks. This also indicates 
that it is possible for drugs of abuse to be present in e-liquid samples without being detected 
depending upon the concentration of the drug, what the drug is, and the e-liquid matrix 
being used. 
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 When interpreting the mass spectra for the detected drugs of abuse added to e-
liquids, the molecular ion peak was not always observed. This is due to the fact that the 
ionization technique used was electron ionization. For the spectra of methamphetamine and 
fentanyl identification was made by comparing the base peaks and other peaks present to 
the National Institute of Standards and Technology (NIST) library (Figures 8-9). For the 
spectrum of nicotine the molecular ion peak was seen as well as an M-1 peak (Figure 10). 
This spectrum was then compared to the NIST library for identification of nicotine. For the 
spectra of cocaine and heroin the molecular ion peak was observed and the spectra were 
compared to the NIST library for identification (Figures 11-12). 
Figure 8: Mass spectrum of methamphetamine. No molecular ion peak was observed in the spectrum of 
methamphetamine (molecular mass: 149.23). This spectrum was compared to the NIST library to confirm 
identification. 
 
Figure 9: Mass spectrum of fentanyl. No molecular ion peak was observed in the spectrum of fentanyl 
(molecular mass: 336.47). This spectrum was compared to the NIST library to confirm identification. 
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Figure 10: Mass spectrum of nicotine. A molecular ion peak as well as a M-1 peak were observed in the 
spectrum of nicotine (molecular mass: 162.23). This spectrum was compared to the NIST library to confirm 
identification. 
 
 
Figure 11: Mass spectrum of cocaine. A molecular ion peak was observed in the spectrum of cocaine 
(molecular mass: 303.35). This spectrum was compared to the NIST library to confirm identification. 
 
 
Figure 12: Mass spectrum of heroin. A molecular ion peak was observed in the spectrum of heroin 
(molecular mass: 369.41). This spectrum was compared to the NIST library to confirm identification. 
 
 
4.1.4 Quantitative Analysis of Spiked Samples 
 The accuracy of the calculated concentrations of the drugs being investigated varied 
widely based on e-liquid matrix as well as which analyte was being quantified. In general 
the calculated concentrations for cocaine and fentanyl were less accurate than those for 
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heroin. With regard to e-liquid matrices, e-liquid samples that fell in the flavor categories 
of menthol and vanilla were less accurate than the e-liquid samples that fell in the flavor 
categories of tobacco, blueberry, and chocolate (Table 9). 
 The components of the e-liquid matrix generally eluted in under nine minutes while 
cocaine, heroin and fentanyl eluted in over nine minutes. This may have affected the 
calculated concentrations. For the VaporFi and Mt. Baker Vapor e-liquid samples the 
calculated concentrations of cocaine, heroin, and fentanyl increased the further the 
compound eluted after the matrix components. However, for the Crazy Vapors, Viking 
Vapors, and ProVape samples the calculated concentrations of cocaine, heroin, and 
fentanyl tended to decrease the further the compound eluted after the matrix components. 
 The complexity of the e-liquid matrix also appeared to have an effect on the 
calculated concentrations. Figure 13 shows a chromatogram of a spiked Mt. Baker Vapor 
Cookie Blaster sample. The calculated concentrations for all three analytes in this matrix 
fell well below the actual spiked concentration. This is also a more complex e-liquid matrix 
compared to the VaporFi Very Vanilla sample seen in Figures 6 and 7, indicating that the 
complexity of the e-liquid matrix plays a role in the ability to quantify drugs of abuse added 
to e-liquids. 
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Figure  13. Chromatogram of Mt. Baker Vapor Cookie Blaster sample zoomed in to show analytes of 
interest. The calculated concentrations of cocaine, heroin, and fentanyl fell well below the target value which 
may be as a result of the overly complex e-liquid matrix when compared to other e-liquid samples, such as 
the ones seen in Figures 6 and 7. 
 
 To quantify the amount of nicotine present in the e-liquid samples used for 
quantitative analysis the calibration curve needed to be extrapolated. A calibration curve 
was not generated to reach the manufacturer stated 24 mg/mL of nicotine to keep from 
saturating the column with nicotine leading to carryover into other samples. Of the 25 e-
liquid samples used for quantitative analysis, 18 of the calculated nicotine concentrations 
fell outside of the ±20% acceptable accuracy range.  
 Three of those 18 samples had calculated nicotine concentrations exceeding 24 
mg/mL and the remaining 15 samples had calculated nicotine concentrations lower than 24 
mg/mL. The VaporFi samples had the greatest number of matrices (four) where the 
calculated nicotine concentration fell within the acceptable range followed by Mt. Baker 
Vapor which had three matrices fall within the acceptable range. None of the Crazy Vapors, 
Viking Vapors, or ProVape matrices fell within the acceptable accuracy range for nicotine 
concentration. 
 The nicotine concentration was also calculated for e-liquid matrices that were 
labeled by the manufacturer as containing 0 mg/mL of nicotine where nicotine was 
detected. Of the 25 e-liquid matrices labeled as containing 0 mg/mL of nicotine 19 of those 
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contained detectable levels of nicotine and 14 of those contained quantifiable levels of 
nicotine. The calculated nicotine concentrations (8.46-32.39 µg/mL) were then compared 
to levels of nicotine found naturally in vegetables belonging to the nightshade family, 
specifically eggplant.51 Nicotine levels in air pollution were also considered when 
conducting this comparison, however, the levels of nicotine calculated from air pollution 
fell so far below the calibration range that it was excluded from further calculations.53 
 Of the 14 e-liquid matrices that contained quantifiable levels of nicotine all 14 had 
statistically higher levels of nicotine than those found naturally in eggplant (0.1 µg/mL). 
This is an important finding because consumers who use these products are under the 
impression that they are using a product that contains no nicotine.  More research is needed 
to determine if the concentration of nicotine present would have any effect on a consumer. 
However, there is a potential that the nicotine present in these samples may keep a user, 
who is attempting to stop using nicotine products or quit smoking, addicted to nicotine. 
 The quantitative results for nicotine in e-liquid matrices demonstrates why 
regulations are needed for these products. In samples that were all labeled to contain 24 
mg/mL of nicotine the range of actual concentrations was from 8.46-32.39 mg/mL. Also, 
detectable levels of nicotine were found in 76% of the matrices tested that were stated to 
contain 0 mg/mL of nicotine. Federal regulation of these products is necessary to protect 
consumers and create some consistency in what are now widely variable matrices. 
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4.2 LC/MS/MS Analysis 
 For analysis by LC/MS/MS, nicotine was excluded from the method that was 
developed and JWH-081, JWH-018, and AM-2201 were included in the method. Nicotine 
was excluded from the method because determining the concentration of nicotine in the 
sample was not the goal of analysis by LC/MS/MS and for forensic casework quantifying 
the concentration of nicotine would provide minimal useful information. The three 
synthetic cannabinoids were included in the LC/MS/MS method and not in the GC/MS 
method because reliable detection and quantitation was not possible in a GC/MS method 
while still keeping the run time under 15 minutes. 
 
4.2.1 Calibration Model 
Quantitative analysis by LC/MS/MS was done at a lower range than by GC/MS. 
This was to keep the instrument detector from becoming saturated, resulting in inaccurate 
quantitation. If LC/MS/MS is used in the analysis of case samples, a dilution step may need 
to be included to ensure that the concentration of the drugs of abuse added to the e-liquid 
matrix falls within the calibration range and does not saturate the detector. 
The calibration model was determined by running seven calibrators over the course 
of nine separate runs with a new set of calibrators being prepared for each run. The 
weighting of the calibration model was determined using the MultiQuantTM software. The 
calibration curves generated were given either no weighting or a weighting of 1/x. The 
accuracy of the quantitation was then observed using both calibration models. A weighting 
of 1/x provided more accurate quantitative results when compared to the calibration model 
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without weighting. From this observation it was determined that a weighting of 1/x would 
be applied to all calibration curves used throughout the data analysis. 
 
4.2.2 Carryover 
 To evaluate any potential carryover in this method, a blank extracted matrix sample 
was run after the highest calibrator which had a concentration of 2000 ng/mL. No carryover 
was observed in the nine runs in which a calibration curve was analyzed. Analysis of the 
blank extracted matrix showed no discernable target analyte peaks among the background 
noise. This shows that the current method is free of any potential carryover up to a 
concentration of 2000 ng/mL for all seven analytes investigated. 
 
4.2.3 Quantitative Analysis of Spiked Samples 
 For analysis by LC/MS/MS all “unknown” samples, at all three concentrations, 
across all ten matrices, were analyzed across three separate runs that were prepared on 
different days and used different calibration curves. The accuracy was calculated for each 
run and across all three runs. Only the results of the accuracy calculations across all three 
runs are shown in Table 14 and in Appendix A, Tables A-I. The acceptable accuracy for 
the calculated concentrations of the target analytes is ±20% of the actual concentration. 
 For the precision calculations, two separate calculations were performed; within-
run precision and between-run precision. The within-run precision calculated the precision 
for the five replicates that were analyzed for each analyte within a particular run. The 
between-run precision is calculated using all replicated for all three runs. The acceptable 
58 
precision for the calculated concentrations of the target analytes is ±20%. Both the accuracy 
and the precision calculations were completed for all seven analytes, at all three “unknown” 
concentrations, across all ten e-liquid matrices. The accuracy and precision calculations 
demonstrated that the ability to quantify drugs of abuse added to e-liquids is dependent on 
the e-liquid matrix, the analyte of interest, and the concentration of the analyte of interest. 
The calculated concentrations of cocaine and fentanyl were found to be accurate at all 
spiked concentrations across all e-liquid matrices. The calculated concentrations of heroin 
were the most inaccurate across all three spiked concentrations and e-liquid matrices. The 
internal standard heroin-d9 was not detected by the instrument and fentanyl-d5 was used 
instead as the internal standard and this may have affected the calculated concentrations 
for heroin.  
 For the quantitation of methamphetamine, the calculated concentrations were 
inaccurate at the spiked concentration of 40 ng/mL (Table 11) but were accurate at the 
higher spiked concentrations of 400 ng/mL (Table 12) and 1500 ng/mL (Table 13). This 
may have been due to matrix interferences that were observed as with GC/MS, but when 
the concentration reached 400 ng/mL the signal from the methamphetamine was sufficient 
to avoid any interference. 
 The calculated concentrations of all the synthetic cannabinoid samples, JWH-081, 
JWH-018, and AM-2201, were found to be inaccurate across all spiked concentrations and 
e-liquid matrices without any noticeable trend (Tables 11-13). This may have been due to 
the fact that the method needed to be further optimized for these analytes to obtain better 
separation. The JWH-081 and JWH-018 compound had very similar retention times which 
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may have affected the ability of the software to calculate a concentration. A sample 
chromatogram can be seen in Figure 14 showing the closeness in retention time. In future 
studies it should be investigated whether developing a separate method that is optimized 
for only synthetic cannabinoids has an effect on the accuracy of the quantitation results. 
 When looking at the accuracy and precision data as a whole (Table 14 and 
Appendix A, Tables A-I) it can be determined that the accuracy fell outside of the 
acceptable ±20% range more often than the precision did. Therefore, while the method was 
inaccurate for certain target analytes, and at certain concentrations, it remained precise.  
Figure 14: LC/MS/MS Chromatogram. The order of elution is methamphetamine (1.67 minutes), heroin 
(1.80 minutes), cocaine (1.89 minutes), fentanyl (2.34 minutes), AM-2201 (4.23 minutes), JWH-018 (4.45 
minutes), and JWH-081 (4.51 minutes). 
   
  
When interpreting the mass spectra for the detected drugs of abuse added to e-
liquids, the molecular ion peak was not observed. This is due to the fact that the ionization 
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technique used was electrospray ionization. Due to the ionization technique, a M+H peak 
was observed in the mass spectra for all target analytes. The ions that were observed in the 
mass spectra are listed in Table 2. 
 
 
4.2.4 LC/MS/MS System Contamination 
For the accuracy and precision studies by LC/MS/MS, a large, irregularly shaped, 
broad peak was observed during run three that was caused by contamination in the 
LC/MS/MS system. This peak was seen in all samples including solvent blanks, negatives, 
double blanks, quality controls, calibrators, and “unknown” samples. This contamination 
led to the inability to quantify JWH-018 during run three. It also led to some of the data for 
the analytes JWH-081 and AM-2201 to be excluded due to interference from the peak 
(Appendix A, Tables D-I). Figure 15 shows a chromatogram that contains the 
contamination peak. It does not appear that the interference from the contamination 
affected the quantitation of any other analytes except for the synthetic cannabinoids. 
 Numerous steps were taken to attempt to find and correct the source of the 
contamination. The first steps taken were to check for contamination in the mobile phases 
used during the analysis. The mobile phase bottles were washed using a methanol/water 
solution and allowed to air dry in a fume hood. Both mobile phases were re-made using 
solvents taken from new, unopened bottles. A series of methanol blanks were then analyzed 
using the same method that had been used for all previous analysis. No change was 
observed in the contamination peak. 
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 The next area that was checked for contamination was the analytical column. The 
analytical column was changed to a new, unused column that was located in the lab and 
the cartridge was changed on the guard column. A series of methanol blanks were then 
analyzed again and no change was observed in the contamination peak. The methanol 
blanks were then analyzed again after the guard column had been removed and only the 
analytical column remained and still no change was observed in the contamination peak. 
 The next area that was checked for contamination was the ion source. The curtain 
plate, and electrode tubing were cleaned using methanol and the electrode was flushed 
using methanol. Analysis of the methanol blanks again showed no change in the 
contamination peak. The injection needle and auto sampler were then checked for 
contamination. The auto sampler was purged twice for a total time of 50 minutes to clean 
the needle and auto sampler and then rinsed several times. When the methanol blanks were 
analyzed, again no change was seen in the contamination peak. 
 The analyte in which the contamination was identified was then re-optimized 
following the same procedure as the original optimization. The re-optimization gave 
slightly different ions for JWH-018. A new method was created using the new ions and the 
old ions for JWH-018. At this point the methanol blanks were analyzed again. In this new 
method the contamination peak was seen for both the new JWH-018 and the old JWH-018 
ions.  
 The last attempt to locate and correct the source of the contamination was to flush 
the entire LC system. The LC system was flushed with 100% methanol for four hours with 
the line that would have gone into the MS/MS instead going into a waste container. After 
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the four hours the series of methanol blanks was analyzed again and still no change was 
seen in the contamination peak. 
 A service engineer from Sciex performed maintenance on the instrument in an 
attempt to determine the source of the contamination. The service engineer discovered that 
the rotor seal was leaking. They disassembled and cleaned the rotor seal before 
reassembling and tightening the seal. A series of methanol blanks was run after this was 
completed and still no change was observed in the contamination peak. 
Figure 15: LC/MS/MS Contaminated Chromatogram. 
 
4.3 Other Analytical Testing Methods 
 Analytical testing of e-liquid samples was done by GC/MS and LC/MS/MS due to 
their ability to provide qualitative and quantitative information for all of the drugs of abuse 
being investigated. Preliminary color tests were not evaluated due to the nature of the e-
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liquid matrices. The e-liquid matrices vary widely among manufacturers and even within 
manufacturers and flavors regarding the color of the liquids. Preliminary color tests were 
not evaluated because the color of the e-liquids would have masked or altered the color of 
the test. Figures 16-20 shows the variability of e-liquid color across different manufacturers 
and nicotine concentrations in the same flavor category. Appendix B shows the color 
variability across the other four flavor categories. The extreme variability in color across 
manufacturers, flavor categories, and nicotine concentrations is part of the reason why 
preliminary color test were not investigated. The lack of ability to complete preliminary 
color tests is also part of the reason that a single method was developed to detect and 
quantify all common drugs of abuse as opposed to separate methods for each drug or 
category of drugs. 
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Figure 16: VaporFi Very Vanilla Samples. The bottle on the left is a VaporFi Very Vanilla sample with a 
nicotine concentration of 0 mg/mL. The bottle in the center is a VaporFi Very Vanilla sample with a nicotine 
concentration of 12 mg/mL. The bottle on the right is a VaporFi Very Vanilla sample with a nicotine 
concentration of 24 mg/mL.  
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Figure 17: Mt. Baker Vapor French Vanilla Samples. The bottle on the left is a Mt. Baker Vapor French 
Vanilla sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Mt. Baker Vapor 
French Vanilla sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a Mt. Baker 
Vapor French Vanilla sample with a nicotine concentration of 24 mg/mL. 
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Figure 18: Crazy Vapors French Vanilla Samples. The bottle on the left is a Crazy Vapors French Vanilla 
sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Crazy Vapors French Vanilla 
sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a Crazy Vapors French Vanilla 
sample with a nicotine concentration of 24 mg/mL. 
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Figure 19: Viking Vapors Vanilla Samples. The bottle on the left is a Viking Vapors Vanilla sample with 
a nicotine concentration of 0 mg/mL. The bottle in the center is a Viking Vapors Vanilla sample with a 
nicotine concentration of 12 mg/mL. The bottle on the right is a Viking Vapors Vanilla sample with a nicotine 
concentration of 24 mg/mL. 
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Figure 20: ProVape Simply Vanilla Samples. The bottle on the left is a ProVape Simply Vanilla sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a ProVape Simply Vanilla sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a ProVape Simply Vanilla sample with a 
nicotine concentration of 24 mg/mL. 
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5. CONCLUSIONS 
5.1 GC/MS 
 Analysis by GC/MS showed that there is little to no consistency between 
components of e-liquids of similar flavors between different manufacturers and that it is 
possible that some e-liquid matrices may contain controlled or toxic substances. 
Component analysis also showed that a lack of regulation can lead to detectable and 
quantifiable levels of nicotine being present in e-liquids that manufacturers claim contain 
no nicotine, as well as inaccurate levels of nicotine in e-liquid samples that were indicated 
to contain 24 mg/mL. 
 Analysis by GC/MS also showed that a qualitative method for the detection of drugs 
of abuse in e-liquid samples is possible, however certain drugs of abuse may be masked by 
e-liquid components of similar retention times. It may also be difficult to detect drugs of 
abuse in e-liquid samples containing high nicotine concentrations if the retention times of 
the drugs of abuse are not known. A quantitative method is possible by GC/MS, however 
the accuracy of the quantitation depends on the e-liquid matrix that is being used with the 
drugs of abuse. The accuracy of the quantitation may also depend upon the extraction 
technique that is used on the e-liquids. However, further research needs to be done to prove 
this theory. 
 
5.2 LC/MS/MS 
 A quantitative method is possible by LC/MS/MS, however the accuracy of the 
quantitation depends on the e-liquid matrix that is being used as well as the target analyte. 
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A dilution step would need to be included in the extraction process for LC/MS/MS analysis 
to be successful on case samples without saturating the detector. When utilizing a dilution 
step a mid-range concentration (400 ng/mL) should be the target concentration for the 
dilution because that range was found to have the most accurate quantitation. 
 The precision of the analysis by LC/MS/MS using a LLE falls within the acceptable 
limit more often than it falls within the unacceptable limit, indicating that while this 
procedure may not be accurate for all of the target analytes it is precise. 
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6. FUTURE STUDIES 
 Future studies involving detection of drugs of abuse in e-liquids should include 
additional extraction techniques that may result in better separation between the e-liquid 
components and the analytes of interest. Separation of synthetic cannabinoids into a 
different analytical method may be necessary. This would allow the method to be 
optimized for synthetic cannabinoids to further separate the peaks and allow for improved 
quantitation. 
 Further work should include spiking an e-liquid with a drug abuse and then simulate 
smoking of the spiked e-liquid. This would allow testing of the emitted vapors, similar to 
the method used to determine nicotine levels in air, to determine how much of the drug of 
abuse is available after vaporization. Once the smoking simulation is completed the interior 
of the cartridge could be tested to determine if there are detectable levels of drug remaining 
in the residue. This could provide useful information in a driving under the influence case 
where the drug being abused is novel and there is little published toxicological data 
available.  
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APPENDIX A:  LC/MS/MS ACCURACY AND PRECISION DATA 
Table A: Accuracy and Precision Results for Viking Vapors Menthol Tobacco. The maximum 
acceptable percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the 
acceptable range are in bold and italic font 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
43.75 9.38 8.44 1.62 N/A 9.03 
JWH-081 (400 
ng/mL) 
421.64 5.41 2.36 4.43 7.35 9.03 
JWH-081 (1500 
ng/mL) 
1654.2 10.28 13.27 14.92 5.84 14.62 
JWH-018 (40 
ng/mL) 
45.71 14.27 2.95 5.84 N/A 5.44 
JWH-018 (400 
ng/mL) 
412.39 3.09 7.04 11.94 N/A 13.48 
JWH-018 (1500 
ng/mL) 
1382.9 -7.80 3.72 11.09 N/A 13.26 
AM-2201 (40 
ng/mL) 
34.49 -13.77 9.58 10.68 27.78 29.44 
AM-2201 (400 
ng/mL) 
365.76 -8.56 11.57 15.41 3.74 16.65 
AM-2201 (1500 
ng/mL) 
1254.1 -16.39 9.97 6.16 14.84 23.34 
Methamphetamine 
(40 ng/mL) 
36.18 -9.53 15.56 16.84 8.32 16.38 
Methamphetamine 
(400 ng/mL) 
421.43 5.36 8.42 6.68 6.88 10.49 
Methamphetamine 
(1500 ng/mL) 
1471.7 -1.88 4.57 6.07 5.48 6.47 
Cocaine (40 
ng/mL) 
41.19 2.97 7.93 8.78 4.57 7.53 
Cocaine (400 
ng/mL) 
427.59 6.89 3.91 3.54 7.87 6.82 
Cocaine (1500 
ng/mL) 
1555.4 3.69 8.06 2.93 6.62 7.21 
Fentanyl (40 
ng/mL) 
39.67 -0.81 3.42 9.77 4.41 7.12 
Fentanyl (400 
ng/mL) 
419.17 4.79 4.71 3.16 5.96 8.03 
Fentanyl (1500 
ng/mL) 
1672.2 11.48 1.92 5.06 6.65 7.78 
Heroin (40 
ng/mL) 
74.19 85.48 0.69 17.49 26.12 24.15 
Heroin (400 
ng/mL) 
820.36 105.09 11.05 9.36 8.41 11.33 
Heroin (1500 
ng/mL) 
2853.2 90.21 3.82 12.13 7.43 13.75 
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Table B: Accuracy and Precision Results for VaporFi Very Vanilla. The maximum acceptable percent 
of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range are in 
bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
38.64 -3.39 12.69 19.07 6.49 16.06 
JWH-081 (400 
ng/mL) 
381.4 -4.65 3.54 5.71 11.44 19.27 
JWH-081 (1500 
ng/mL) 
1472.4 -1.84 0.56 6.28 7.71 16.95 
JWH-018 (40 
ng/mL) 
29.18 -27.05 12.15 18.81 N/A 24.95 
JWH-018 (400 
ng/mL) 
434.38 8.59 2.50 9.70 N/A 8.25 
JWH-018 (1500 
ng/mL) 
1660.94 10.73 3.46 3.04 N/A 3.72 
AM-2201 (40 
ng/mL) 
38.29 -4.27 12.22 38.01 10.66 52.11 
AM-2201 (400 
ng/mL) 
524.21 31.05 12.17 3.49 3.02 22.16 
AM-2201 (1500 
ng/mL) 
2100.76 40.05 4.92 6.54 3.55 25.28 
Methamphetamine 
(40 ng/mL) 
39.29 -1.78 9.36 8.05 9.04 21.19 
Methamphetamine 
(400 ng/mL) 
387.30 -3.17 7.56 9.41 4.44 0.11 
Methamphetamine 
(1500 ng/mL) 
1367.69 -8.82 1.01 5.47 11.94 14.19 
Cocaine (40 
ng/mL) 
42.14 2.81 2.07 7.59 7.09 6.67 
Cocaine (400 
ng/mL) 
403.41 0.85 4.25 4.13 4.55 5.93 
Cocaine (1500 
ng/mL) 
1530.86 2.06 4.73 0.58 4.67 5.58 
Fentanyl (40 
ng/mL) 
38.62 -3.46 7.04 5.37 10.1 10.58 
Fentanyl (400 
ng/mL) 
402.60 0.65 5.26 5.46 4.56 8.54 
Fentanyl (1500 
ng/mL) 
1472.45 -1.84 1.05 1.59 4.58 12.12 
Heroin (40 
ng/mL) 
36.50 -8.74 9.38 6.77 13.46 11.94 
Heroin (400 
ng/mL) 
387.91 -3.02 4.19 5.35 5.11 5.86 
Heroin (1500 
ng/mL) 
1424.66 -5.02 3.41 3.28 5.85 4.66 
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Table C: Accuracy and Precision Results for Mt. Baker Vapors East Coast Tobacco. The maximum 
acceptable percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the 
acceptable range are in bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
20.16 -49.59 40.99 14.31 9.13 51.86 
JWH-081 (400 
ng/mL) 
328.89 -17.78 9.38 7.15 8.14 16.91 
JWH-081 (1500 
ng/mL) 
1110.8 -25.94 9.65 9.99 5.46 18.69 
JWH-018 (40 
ng/mL) 
20.68 -48.31 22.68 12.61 N/A 22.44 
JWH-018 (400 
ng/mL) 
438.28 9.57 3.49 5.88 N/A 7.70 
JWH-018 (1500 
ng/mL) 
1617.3 7.82 7.37 9.47 N/A 11.12 
AM-2201 (40 
ng/mL) 
74.69 86.71 10.87 7.97 9.97 29.98 
AM-2201 (400 
ng/mL) 
943.67 135.9 4.05 7.07 5.97 18.83 
AM-2201 (1500 
ng/mL) 
2990.2 99.34 12.96 10.99 12.17 18.96 
Methamphetamine 
(40 ng/mL) 
32.44 -18.91 10.38 9.10 5.03 19.69 
Methamphetamine 
(400 ng/mL) 
370.38 -7.40 7.05 2.08 7.94 18.83 
Methamphetamine 
(1500 ng/mL) 
1245.3 -16.98 9.59 2.75 7.68 15.52 
Cocaine (40 
ng/mL) 
38.79 -3.00 5.00 4.94 5.54 7.58 
Cocaine (400 
ng/mL) 
406.89 1.72 2.16 6.77 6.43 6.68 
Cocaine (1500 
ng/mL) 
1482.8 -1.15 0.48 2.69 2.00 4.42 
Fentanyl (40 
ng/mL) 
38.14 -4.65 6.29 6.64 9.96 11.36 
Fentanyl (400 
ng/mL) 
408.15 2.04 3.85 4.63 3.25 9.78 
Fentanyl (1500 
ng/mL) 
1438.2 -4.12 4.53 4.31 4.67 8.97 
Heroin (40 
ng/mL) 
35.45 -11.37 8.01 10.44 19.63 19.99 
Heroin (400 
ng/mL) 
480.85 20.21 4.04 8.55 7.03 9.96 
Heroin (1500 
ng/mL) 
1599.2 6.61 6.11 2.65 1.84 8.69 
 
75 
Table D: Accuracy and Precision Results for Crazy Vapors Menthol. The maximum acceptable percent 
of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range are in 
bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
44.37 10.92 6.91 N/A N/A N/A 
JWH-081 (400 
ng/mL) 
370.03 -7.49 13.65 17.01 N/A 16.66 
JWH-081 (1500 
ng/mL) 
1569.3 4.62 3.38 4.37 N/A 13.20 
JWH-018 (40 
ng/mL) 
42.84 7.10 9.48 12.59 N/A 11.96 
JWH-018 (400 
ng/mL) 
374.48 -6.38 14.83 4.81 N/A 10.47 
JWH-018 (1500 
ng/mL) 
1436.8 -4.21 10.23 5.38 N/A 10.34 
AM-2201 (40 
ng/mL) 
51.52 28.81 2.86 N/A N/A N/A 
AM-2201 (400 
ng/mL) 
385.09 -3.72 20.01 9.18 N/A 15.22 
AM-2201 (1500 
ng/mL) 
1668.6 11.24 2.92 8.79 N/A 7.53 
Methamphetamine 
(40 ng/mL) 
30.23 -24.42 9.87 13.68 9.26 31.53 
Methamphetamine 
(400 ng/mL) 
340.39 -14.90 3.93 9.64 6.20 16.15 
Methamphetamine 
(1500 ng/mL) 
1277.14 -14.86 3.17 5.21 3.08 12.99 
Cocaine (40 
ng/mL) 
38.94 -2.64 7.92 5.91 6.13 8.04 
Cocaine (400 
ng/mL) 
411.45 2.86 10.00 3.68 5.56 7.44 
Cocaine (1500 
ng/mL) 
1525.5 1.70 8.11 2.69 5.39 6.74 
Fentanyl (40 
ng/mL) 
39.43 -1.43 7.03 10.10 7.80 10.37 
Fentanyl (400 
ng/mL) 
404.67 1.17 7.44 4.17 8.25 8.06 
Fentanyl (1500 
ng/mL) 
1518.6 1.24 2.86 4.18 7.18 5.75 
Heroin (40 
ng/mL) 
61.84 54.59 6.63 13.19 23.64 25.02 
Heroin (400 
ng/mL) 
754.68 88.67 11.29 7.44 6.94 9.77 
Heroin (1500 
ng/mL) 
2285.5 52.37 15.41 7.05 7.09 15.15 
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Table E: Accuracy and Precision Results for Crazy Vapors French Vanilla. The maximum acceptable 
percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range 
are in bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
38.59 -3.53 18.06 N/A N/A N/A 
JWH-081 (400 
ng/mL) 
304.88 -23.77 11.34 9.45 N/A 21.96 
JWH-081 (1500 
ng/mL) 
984.01 -34.34 13.29 31.39 N/A 23.93 
JWH-018 (40 
ng/mL) 
38.65 -3.38 3.73 13.12 N/A 35.13 
JWH-018 (400 
ng/mL) 
343.54 -14.12 4.09 7.40 N/A 7.16 
JWH-018 (1500 
ng/mL) 
1407.6 -6.16 10.23 7.65 N/A 9.78 
AM-2201 (40 
ng/mL) 
70.11 75.28 8.74 31.61 N/A 23.39 
AM-2201 (400 
ng/mL) 
800.37 100.09 17.07 6.05 N/A 17.20 
AM-2201 (1500 
ng/mL) 
3162.71 110.85 15.35 10.75 N/A 15.29 
Methamphetamine 
(40 ng/mL) 
31.86 -20.36 3.54 4.97 6.15 32.57 
Methamphetamine 
(400 ng/mL) 
359.06 -10.24 14.37 6.82 7.92 17.00 
Methamphetamine 
(1500 ng/mL) 
1237.4 -17.50 10.46 9.13 3.82 21.03 
Cocaine (40 
ng/mL) 
37.82 -5.44 8.03 5.32 5.22 6.35 
Cocaine (400 
ng/mL) 
414.4 3.59 6.86 6.45 5.27 6.42 
Cocaine (1500 
ng/mL) 
1468.5 -2.10 6.43 4.16 5.34 6.55 
Fentanyl (40 
ng/mL) 
37.66 -5.84 8.93 2.58 8.12 13.33 
Fentanyl (400 
ng/mL) 
402.77 0.69 1.43 6.08 3.97 5.00 
Fentanyl (1500 
ng/mL) 
1488.1 -0.79 1.53 5.28 4.04 5.68 
Heroin (40 
ng/mL) 
36.80 -7.99 3.32 22.58 17.77 28.82 
Heroin (400 
ng/mL) 
574.78 43.62 6.29 6.85 6.05 10.61 
Heroin (1500 
ng/mL) 
2160.3 44.02 8.92 3.93 4.66 7.73 
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Table F: Accuracy and Precision Results for Viking Vapors Menthol Tobacco. The maximum 
acceptable percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the 
acceptable range are in bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
43.75 9.38 8.44 1.62 N/A 9.03 
JWH-081 (400 
ng/mL) 
421.64 5.41 2.36 4.43 7.35 9.03 
JWH-081 (1500 
ng/mL) 
1654.2 10.28 13.27 14.92 5.84 14.62 
JWH-018 (40 
ng/mL) 
45.71 14.27 2.95 5.84 N/A 5.44 
JWH-018 (400 
ng/mL) 
412.39 3.09 7.04 11.94 N/A 13.48 
JWH-018 (1500 
ng/mL) 
1382.9 -7.80 3.72 11.09 N/A 13.26 
AM-2201 (40 
ng/mL) 
34.49 -13.77 9.58 10.68 27.78 29.44 
AM-2201 (400 
ng/mL) 
365.76 -8.56 11.57 15.41 3.74 16.65 
AM-2201 (1500 
ng/mL) 
1254.1 -16.39 9.97 6.16 14.84 23.34 
Methamphetamine 
(40 ng/mL) 
36.18 -9.53 15.56 16.84 8.32 16.38 
Methamphetamine 
(400 ng/mL) 
421.43 5.36 8.42 6.68 6.88 10.49 
Methamphetamine 
(1500 ng/mL) 
1471.7 -1.88 4.57 6.07 5.48 6.47 
Cocaine (40 
ng/mL) 
41.19 2.97 7.93 8.78 4.57 7.53 
Cocaine (400 
ng/mL) 
427.59 6.89 3.91 3.54 7.87 6.82 
Cocaine (1500 
ng/mL) 
1555.4 3.69 8.06 2.93 6.62 7.21 
Fentanyl (40 
ng/mL) 
39.67 -0.81 3.42 9.77 4.41 7.12 
Fentanyl (400 
ng/mL) 
419.17 4.79 4.71 3.16 5.96 8.03 
Fentanyl (1500 
ng/mL) 
1672.2 11.48 1.92 5.06 6.65 7.78 
Heroin (40 
ng/mL) 
74.19 85.48 0.69 17.49 26.12 24.15 
Heroin (400 
ng/mL) 
820.36 105.09 11.05 9.36 8.41 11.33 
Heroin (1500 
ng/mL) 
2853.2 90.21 3.82 12.13 7.43 13.75 
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Table G: Accuracy and Precision Results for Viking Vapors Vanilla. The maximum acceptable percent 
of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range are in 
bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
38.82 -2.95 13.39 24.73 N/A 21.05 
JWH-081 (400 
ng/mL) 
381.94 -4.52 16.27 13.99 10.85 16.95 
JWH-081 (1500 
ng/mL) 
1175.4 -21.64 15.25 5.27 6.84 18.86 
JWH-018 (40 
ng/mL) 
39.86 -0.36 12.72 13.15 N/A 13.02 
JWH-018 (400 
ng/mL) 
353.38 -11.65 12.36 8.27 N/A 17.09 
JWH-018 (1500 
ng/mL) 
1126.1 -24.93 12.61 8.13 N/A 12.22 
AM-2201 (40 
ng/mL) 
41.01 2.53 9.58 13.95 24.62 21.61 
AM-2201 (400 
ng/mL) 
378.74 -5.32 9.68 13.17 17.33 16.63 
AM-2201 (1500 
ng/mL) 
1585.8 5.72 5.08 12.43 8.86 10.64 
Methamphetamine 
(40 ng/mL) 
29.78 -25.55 13.55 7.34 12.05 22.04 
Methamphetamine 
(400 ng/mL) 
380.10 -4.97 6.62 7.61 8.69 9.19 
Methamphetamine 
(1500 ng/mL) 
1377.1 -8.19 6.16 6.82 6.68 10.03 
Cocaine (40 
ng/mL) 
40.38 0.95 9.82 6.44 4.49 9.68 
Cocaine (400 
ng/mL) 
418.71 4.68 7.05 4.11 4.46 6.36 
Cocaine (1500 
ng/mL) 
1517.2 1.15 7.12 5.75 2.11 7.42 
Fentanyl (40 
ng/mL) 
35.79 -10.53 4.96 4.77 7.49 12.86 
Fentanyl (400 
ng/mL) 
419.41 4.85 7.47 9.28 2.34 8.69 
Fentanyl (1500 
ng/mL) 
1575.5 5.03 6.10 6.19 3.99 8.39 
Heroin (40 
ng/mL) 
87.31 118.27 6.21 2.35 22.69 23.10 
Heroin (400 
ng/mL) 
1072.4 168.1 7.23 4.83 7.47 25.23 
Heroin (1500 
ng/mL) 
3326.7 121.78 7.18 8.94 2.95 21.36 
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Table H: Accuracy and Precision Results for ProVape Icy Menthol. The maximum acceptable percent 
of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range are in 
bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
57.18 42.94 22.22 12.25 N/A 20.03 
JWH-081 (400 
ng/mL) 
426.24 6.56 7.84 17.61 N/A 26.93 
JWH-081 (1500 
ng/mL) 
1634.7 8.98 16.35 15.79 N/A 29.19 
JWH-018 (40 
ng/mL) 
46.03 15.06 8.72 N/A N/A N/A 
JWH-018 (400 
ng/mL) 
392.42 -1.89 8.41 12.18 N/A 12.53 
JWH-018 (1500 
ng/mL) 
1523.3 1.55 11.15 8.59 N/A 12.81 
AM-2201 (40 
ng/mL) 
29.80 -25.49 18.51 N/A N/A N/A 
AM-2201 (400 
ng/mL) 
374.38 -6.40 6.32 13.67 N/A 11.24 
AM-2201 (1500 
ng/mL) 
1369.3 -8.71 18.11 6.20 N/A 13.58 
Methamphetamine 
(40 ng/mL) 
34.55 -13.63 32.77 5.40 7.85 35.41 
Methamphetamine 
(400 ng/mL) 
301.66 -24.59 14.92 5.41 10.10 37.75 
Methamphetamine 
(1500 ng/mL) 
1235.5 -17.63 13.61 2.80 7.71 19.84 
Cocaine (40 
ng/mL) 
38.72 -3.20 7.88 2.43 3.85 6.26 
Cocaine (400 
ng/mL) 
421.99 5.49 9.05 5.38 6.81 7.48 
Cocaine (1500 
ng/mL) 
1532.9 2.19 4.34 7.01 3.69 6.94 
Fentanyl (40 
ng/mL) 
37.11 -7.23 4.17 8.34 6.12 14.20 
Fentanyl (400 
ng/mL) 
408.07 2.02 7.56 3.39 2.77 6.42 
Fentanyl (1500 
ng/mL) 
1484.2 -1.06 8.97 5.56 10.08 9.54 
Heroin (40 
ng/mL) 
16.61 -58.46 12.80 25.07 28.45 35.36 
Heroin (400 
ng/mL) 
349.7 -12.57 11.23 3.23 8.39 9.74 
Heroin (1500 
ng/mL) 
1101.3 -26.57 14.67 3.78 9.10 13.79 
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Table I: Accuracy and Precision Results for ProVape Simply Vanilla. The maximum acceptable 
percent of accuracy and bias allowed is ±20%. Calculated values that fall outside of the acceptable range 
are in bold and italic font. 
 
 
Mean 
(μg/mL) 
Accuracy 
(%) 
Within-
Run 
Precision 
(%) Run 1 
Within-
Run 
Precision 
(%) Run 2 
Within-
Run 
Precision 
(%) Run 3 
Between-
Run 
Precision 
(%) 
JWH-081 (40 
ng/mL) 
69.51 73.79 13.76 11.36 N/A 19.45 
JWH-081 (400 
ng/mL) 
590.01 47.50 16.65 9.96 N/A 19.79 
JWH-081 (1500 
ng/mL) 
1630.6 8.71 1.67 6.86 N/A 7.82 
JWH-018 (40 
ng/mL) 
41.49 3.72 7.68 7.03 N/A 10.97 
JWH-018 (400 
ng/mL) 
383.59 -4.10 10.89 9.44 N/A 10.13 
JWH-018 (1500 
ng/mL) 
1420.4 -5.31 7.05 9.71 N/A 10.72 
AM-2201 (40 
ng/mL) 
18.84 -52.91 15.97 N/A N/A N/A 
AM-2201 (400 
ng/mL) 
294.01 -26.49 12.47 8.29 N/A 11.81 
AM-2201 (1500 
ng/mL) 
1151.6 -23.23 9.56 21.09 N/A 16.96 
Methamphetamine 
(40 ng/mL) 
31.29 -21.76 16.60 10.08 7.58 34.38 
Methamphetamine 
(400 ng/mL) 
344.54 -13.86 9.79 5.67 5.93 21.23 
Methamphetamine 
(1500 ng/mL) 
1250.9 -16.6 7.10 8.07 4.77 19.61 
Cocaine (40 
ng/mL) 
37.21 -6.98 6.59 2.83 6.88 7.63 
Cocaine (400 
ng/mL) 
398.52 -0.37 8.77 3.62 5.14 6.77 
Cocaine (1500 
ng/mL) 
1532.8 2.18 6.49 4.86 4.96 6.22 
Fentanyl (40 
ng/mL) 
34.18 -14.53 9.19 3.60 9.22 11.67 
Fentanyl (400 
ng/mL) 
393.69 -1.57 7.19 6.31 3.62 8.16 
Fentanyl (1500 
ng/mL) 
1518.9 1.26 6.57 4.98 5.37 6.19 
Heroin (40 
ng/mL) 
64.18 60.46 2.53 15.80 31.16 27.11 
Heroin (400 
ng/mL) 
875.57 118.89 9.01 3.92 9.49 14.08 
Heroin (1500 
ng/mL) 
2867.6 91.18 12.35 12.53 4.03 12.96 
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APPENDIX B:  ELECTRONIC CIGARETTE LIQUID PHOTOGRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A: VaporFi Classic Tobacco Samples. The bottle on the left is a VaporFi Classic Tobacco sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a VaporFi Classic Tobacco sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a VaporFi Classic Tobacco sample with a 
nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B: Mt. Baker Vapor East Coast Tobacco Samples. The bottle on the left is a Mt. Baker Vapor East 
Coast Tobacco sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Mt. Baker 
Vapor East Coast Tobacco sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a 
Mt. Baker Vapor East Coast Tobacco sample with a nicotine concentration of 24 mg/mL. 
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Figure C: Crazy Vapors Cured Tobacco Samples. The bottle on the left is a Crazy Vapors Cured Tobacco 
sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Crazy Vapors Cured Tobacco 
sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a Crazy Vapors Cured Tobacco 
sample with a nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D: Viking Vapors Tobacco Samples. The bottle on the left is a Viking Vapors Tobacco sample with 
a nicotine concentration of 0 mg/mL. The bottle in the center is a Viking Vapors Tobacco sample with a 
nicotine concentration of 12 mg/mL. The bottle on the right is a Viking Vapors Tobacco sample with a 
nicotine concentration of 24 mg/mL. 
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Figure E: ProVape Ken’s Tobacco Samples. The bottle on the left is a ProVape Ken’s Tobacco sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a ProVape Ken’s Tobacco sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a ProVape Ken’s Tobacco sample with a 
nicotine concentration of 24 mg/mL. 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F: VaporFi Menthol Ice Samples. The bottle on the left is a VaporFi Menthol Ice sample with a 
nicotine concentration of 0 mg/mL. The bottle in the center is a VaporFi Menthol Ice sample with a nicotine 
concentration of 12 mg/mL. The bottle on the right is a VaporFi Menthol Ice sample with a nicotine 
concentration of 24 mg/mL.  
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Figure G: Mt. Baker Vapor Menthol Samples. The bottle on the left is a Mt. Baker Vapor Menthol sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a Mt. Baker Vapor Menthol sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a Mt. Baker Vapor Menthol sample with a 
nicotine concentration of 24 mg/mL. 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure H: Crazy Vapors Menthol Samples. The bottle on the left is a Crazy Vapors Menthol sample with 
a nicotine concentration of 0 mg/mL. The bottle in the center is a Crazy Vapors Menthol sample with a 
nicotine concentration of 12 mg/mL. The bottle on the right is a Crazy Vapors Menthol sample with a nicotine 
concentration of 24 mg/mL. 
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Figure I: Viking Vapors Menthol Tobacco Samples. The bottle on the left is a Viking Vapors Menthol 
Tobacco sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Viking Vapors 
Menthol Tobacco sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a Viking 
Vapors Menthol Tobacco sample with a nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure J: ProVape Icy Menthol Samples. The bottle on the left is a ProVape Icy Menthol sample with a 
nicotine concentration of 0 mg/mL. The bottle in the center is a ProVape Icy Menthol sample with a nicotine 
concentration of 12 mg/mL. The bottle on the right is a ProVape Icy Menthol sample with a nicotine 
concentration of 24 mg/mL. 
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Figure K: VaporFi Blueberry Blast Samples. The bottle on the left is a VaporFi Blueberry Blast sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a VaporFi Blueberry Blast sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a VaporFi Blueberry Blast sample with a 
nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure L: Mt. Baker Vapor Blueberry Samples. The bottle on the left is a Mt. Baker Vapor Blueberry 
sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Mt. Baker Vapor Blueberry 
sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a Mt. Baker Vapor Blueberry 
sample with a nicotine concentration of 24 mg/mL. 
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Figure M: Crazy Vapors Blueberry Samples. The bottle on the left is a Crazy Vapors Blueberry sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a Crazy Vapors Blueberry sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a Crazy Vapors Blueberry sample with a 
nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure N: Viking Vapors Blueberry Samples. The bottle on the left is a Viking Vapors Blueberry sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a Viking Vapors Blueberry sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is a Viking Vapors Blueberry sample with a 
nicotine concentration of 24 mg/mL. 
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Figure O: ProVape Frosted Blueberry Samples. The bottle on the left is a ProVape Frosted Blueberry 
sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a ProVape Frosted Blueberry 
sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a ProVape Frosted Blueberry 
sample with a nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure P: VaporFi Chocolate Delight Samples. The bottle on the left is a VaporFi Chocolate Delight 
sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a VaporFi Chocolate Delight 
sample with a nicotine concentration of 12 mg/mL. The bottle on the right is a VaporFi Chocolate Delight 
sample with a nicotine concentration of 24 mg/mL. 
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Figure Q: Mt. Baker Vapor Cookie Blaster Samples. The bottle on the left is a Mt. Baker Vapor Cookie 
Blaster sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Mt. Baker Vapor 
Cookie Blaster sample with a nicotine concentration of 12 mg/mL. The bottle on the right is Mt. Baker Vapor 
Cookie Blaster sample with a nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R: Crazy Vapors Double Chocolate Samples. The bottle on the left is a Crazy Vapors Double 
Chocolate sample with a nicotine concentration of 0 mg/mL. The bottle in the center is a Crazy Vapors 
Double Chocolate sample with a nicotine concentration of 12 mg/mL. The bottle on the right is Crazy Vapors 
Double Chocolate sample with a nicotine concentration of 24 mg/mL. 
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Figure S: Viking Vapors Chocolate Samples. The bottle on the left is a Viking Vapors Chocolate sample 
with a nicotine concentration of 0 mg/mL. The bottle in the center is a Viking Vapors Chocolate sample with 
a nicotine concentration of 12 mg/mL. The bottle on the right is Viking Vapors Chocolate sample with a 
nicotine concentration of 24 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure T: ProVape Chocolate Samples. The bottle on the left is a ProVape Chocolate sample with a 
nicotine concentration of 0 mg/mL. The bottle in the center is a ProVape Chocolate sample with a nicotine 
concentration of 12 mg/mL. The bottle on the right is ProVape Chocolate sample with a nicotine 
concentration of 24 mg/mL. 
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